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Non-transfusional hemocomponents are autogenous products used in several surgical fields 
obtained by the centrifugation of a blood sample from a patient and able to promote hard and 
soft tissue regeneration, local haemostasis, and the acceleration of wound healing.  
The aim of this PhD thesis was the validation of an innovative protocol for the Guided Bone 
Regeneration (GBR) technique using second-generation autologous platelet concentrates, 
Leukocytes and Platelet-rich Fibrin (L-PRF), in post-extraction sockets of patients in need of 
dental avulsions and successive implant prosthetic rehabilitation, evaluating its ability to 
prevent alveolar bone resorption and promote bone regeneration. 
The secondary aim was the design and development of a multicomposite loaded with 
antimicrobic and antioxidant agents, to be applied wrapped in the L-PRF membrane, 
enhancing its regenerative properties. 
This project cohering with the National Operational Program (PON) “Research and 
Innovation” (R&I) 2014-2020 funding by the Italian Ministry of Education, University and 
Research, aimed to promote the research and the innovation of the country, with a particular 




Teeth extractions are common practices in oral surgery, but they are often followed by 
alveolar bone resorption and remodeling processes, that can lead to significant changes in 
ridge dimensions, both horizontal and vertical. Dental implants are the most common choice 
to replace tooth extracted, but to achieve the ideal functional and aesthetic prosthetic 
rehabilitation, the adequate alveolar bone volume is required. 
To prevent the development of severe bone resorption and provide the adequate bone height 
and width for implant restoration, several surgical techniques have been proposed, such as 
guided bone regeneration procedures (GBR) and alveolar ridge preservation (ARP). The use 
of resorbable membranes and autologous bone grafts is currently the “gold standard” of the 
GBR procedures even though they present some drawbacks such as morbidity of the 
additional surgical site, limited graft accessibility, risk of clinical complication, prolonged 
operation time and high cost of interventions. The use of non-transfusional hemocomponents 
in GBR and ARP techniques have been defined as an innovative strategy to achieve soft and 
hard tissue healing in the post-extraction sockets, overcoming the drawbacks of the traditional 
procedures. Recently, leukocyte and platelet-rich fibrin (L-PRF) and its derivate PRF-Block 
has been applied in regenerative procedures, exhibited promising results. 
Indeed, the aim of this thesis was the validation of a GBR protocol based on the use of L-PRF 
on the post-extraction sockets of patients in need of dental extraction and successive implant 
prosthetic rehabilitation. The ability of these systems to prevent alveolar bone resorption in 
the alveolus and promote bone regeneration in various-size bony defects have been evaluated 
to validate the proposed surgical procedure. Five patients were treated by GBR procedures to 
regenerate three-dimensional bone defects and, in other ten patients, ARPs were performed to 
prevent alveolar bone resorption. The achievement of the adequate ridge dimensions allowed 
successful implant-based rehabilitation in all the enrolled subjects. The obtained outcomes in 
terms of bone healing and tissue regeneration were in accordance with the literature and 
reinforce the effective role of L-PRF and its derivate in oral surgical procedures.  
The secondary aim was the development of a multicomposite biomaterial based on 
nanostructured lipid carriers loaded with lipophilic antioxidant compound and entrapped in a 
biodegradable matrix loaded with an antibiotic, to be applied in association with the L-PRF 




 Background, Rationale and Objectives  
a) Leucocytes and Platelet rich Fibrin (L-PRF) for Guided Bone Regeneration 
 and Alveolar Ridge Preservation   
1.1 Mechanisms of Bone Formation and Development 
Bone is a connective tissue providing protection for internal organs and tissues, mechanical 
support for muscles, depot for the systemic mineral homeostasis, such as calcium, phosphate, 
amino acids, and bicarbonate, and mastication. It also performs metabolic functions, including 
the secretion of hormones that regulate both mineral and energy metabolism. To accomplish 
these functions, two types of bone could be recognized, with different morphology and 
functionality1. 
The cortical component, or compact bone, accounts for almost 80% of skeletal mass, owns 
mechanical and protective functions and is located in diaphyseal regions of long bones. It is 
characterized by densely formed collagen fibrils surrounding a central channel for blood 
vessels, lymphatics, and nerves.  
Trabecular bone, also known as cancellous bone, is located inside the cortical one at the ends 
of long bones, where the compact is thinner. It is a spongy tissue made by a porous network 
of thin wires, called trabeculae, having metabolic functions and able to transfers mechanical 
loads from the articular surface to the cortical bone and absorb shock for its hydraulic 
properties2. 
The surface to volume ratio in cortical bone is much lower than in trabecular, that has less 
calcium but more water content and a higher turnover1. Indeed, bone tissue has a dynamic 
nature, characterized by the constant formation of new bone and dissolution of old, injured, or 
unnecessary ones for repair or calcium release and it can constantly adapt to the surrounding 
environment.  
Bone is made up of cells and extracellular matrix and the osteogenesis, the process of bone 
formation, can be distinguished in endochondral, intramembranous, or sutural3. 
The extracellular matrix is a highly mineralized tissue, produced by osteoblasts. These cells 
are responsible for the new bone formation, derived from multipotent mesenchymal stem cells 
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(MSCs) in the bone marrow and placed especially in the growing portions of bone. By 
contrary, the cells responsible for bone resorption, or breakdown, are the osteoclasts derived 
from hematopoietic progenitors (i.e., monocytes/macrophages) found also in the bone 
marrow4. The remodeling process of bone exceeds in bone formation during the growth stages 
of childhood, adolescence and into young adulthood; after this stage, bone resorption 
outperforms bone formation, leading to a gradual and progressive bone loss2. The 
endocortical surface is exposed to the marrow and the solid bone and often shows a higher 
bone turnover than other trabecular or cortical surfaces1.  
Bone regeneration is a complex, well-orchestrated physiological process of bone formation, 
occurring in normal fracture healing, and involved in a continuous remodeling throughout 
adult life5. Bone turnover, and, consequently, bone mass can be influenced by several 
systemic factors, such as nutrition, hormonal status, exposure to smoking, alcohol, physical 
inactivity, or particular drugs3. Besides, on account of the declining estrogens at menopause, 
usually, women have a more rapid bone loss and a greater risk of osteoporosis than men6. 
The differentiation of MSCs in osteoblast is stimulated by specific transcription factors since 
these cells are the progenitors of either adipocytes, chondrocytes, or myoblasts7,8. The 
essential regulators of osteoblast differentiation are runt-related transcription factor 2 
(RUNX2) and Osterix downstream of RUNX2 that, during the proliferation phase, stimulate a 
morphological change from osteoprogenitors to pre-osteoblasts, which start to synthetize bone 
matrix and alkaline phosphatase (ALP)9. Mature osteoblasts then regulate bone matrix 
mineralization and produce osteocalcin (OCN) that, with ALP, are used as clinical markers of 
bone formation9. 
Instead, osteoclasts differentiation is promoted by a bond between receptor activator of NF-
kB ligand (Tnfsf11/RANKL) secreted by osteoblasts and RANK receptors located on the 
surface of hematopoietic cells10. During osteoclastogenesis, bone marrow macrophages 
(BMMs) differentiate into tartrate-resistant acid phosphatase (TRAP)-positive pre-osteoclasts, 
which then fuse to form mature osteoclasts7,11. RANKL and macrophage colony-stimulating 
factor (M-CSF) are two markers of osteoclasts formation11, while osteoblast-secreted 




Systemic and local factors, such as bone morphogenetic proteins, canonical wingless (Wnt)/β-
catenin signaling pathway, insulin-like growth factor (IGF), mechanical forces, estrogen and 
other hormones could influence transcription factors activity, thus bone turnover4,10. 
1.2 Alveolar bone  
The portion of maxilla and mandible that forms tooth sockets is characterized by a rapid 
remodeling due to tooth eruption and functional demands; it provides support to the teeth by 
an attachment apparatus based on three tissues: root cementum, periodontal ligament and 
alveolar bone13,14 (Figure 1). 
 
Figure 1 Periodontal tissues: gingiva, periodontal ligament, root cementum, and alveolar bone15. 
The alveolar bone develops into an intramembranous bone formation during the creation of 
the mandible and maxilla, in concomitance of the primary dentition. During this process, bone 
develops around the inferior alveolar nerve and the incisive nerve, forming the bony trough 
within which the nerve will lay, and that will house the developing tooth buds13. It is the 
major support structure for the teeth, provides a framework to the marrow and attachment to 
the forming periodontal ligament (PDL) and the muscles; it also absorbs the pressures 
generated during tooth contacts and serves as a reservoir of Calcium and other ions16.  
Two components could be described: the alveolar bone proper and alveolar bone process. 
The former provides the attachment site for the PDL, lining the tooth socket17. The insertion 
of Sharpey’s fibres into alveolar bone proper is the key to tooth root housing. These fibres are 
organized in bundles and calcified within the bone to provide a strong attachment between 
tooth and bone17. The latter type houses the developing tooth buds first and once erupted, the 
roots of the teeth and provides structural support for the dentition; this type is usually affected 
by tooth loss, resorbing after becoming unnecessary.  
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The bone process is composed of an outer layer of cortical bone and an inner region of 
cancellous bone and contains the blood vessels and nerves that support the teeth and the bone 
marrow with the adipose and osteogenic cells and the hemopoietic tissue.  
The portion on alveolar bone process nearest to the Sharpey’s fibres is also known as Bundle 
Bone, due to the presence of the fibre bundles and it plays a key role into tooth movement and 
disease processes involving the periodontium18. Instead, the Lamellar Bone is a section of the 
alveolar bone proper, perforated by numerous small foramina that allow nerve and vessel 
irrigation until the PDL tissues. The coronal margin of the bone, lining the socket, becomes 
the alveolar crest, that results more mineralized than the bone adjacent to the apex of the 
tooth13. 
Thus, in general, alveolar bone has bundle bone organized in parallel layers with the coronal-
apical direction of the tooth and Sharpey’s fibres spread obliquely from the lamella of the 
bone surrounding the socket walls and continuous with the periodontal ligament fibres.  
The alveolar bone consists of approximately around 23% inorganic components, 37% organic 
matrix, and 40% water17. The former represents the two-third of the total composition and 
contains hydroxyapatite crystals, minerals like calcium and phosphate along with hydroxyl, 
carbonate and citrate and Mg, Na, K, Fl ions. The organic elements consist of cellular 
components, the osteogenic cells, and matrix made by collagen (primarily Type I) and 
noncollagenous proteins such as osteocalcin, osteonectin, BMP, Sialoprotein, 
Phosphoproteins and Proteoglycan19. 
Cellular components 
• Osteoblasts: the most active secretory cells in bone, responsible to produce the organic 
matrix of bone, thus type I collagen and various other noncollagenous bone and plasma 
proteins. They have a mesenchymal origin and when fully differentiated show a cuboidal 
or elongated shape that holds a percentage of bony surfaces depending on age and 
anatomical site. The alveolar bone osteoblasts in the innermost surface of tooth alveolus 
are arranged to create a suitable accommodation for the Sharpey’s fibres inserted into the 
bone. The periodontal ligament fibres interleave the osteoblasts in the continuous 
remodeling of the alveolar bone matrix, based on the alternation of temporary detachment 
of small portions of the periodontal ligament from the alveolus with a new synthesis of 
the periodontal ligament by fibroblasts and new alveolar bone production by osteoblasts; 
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this cycle allows the maintenance of tooth biomechanical function19. Mature osteoblast 
may undergo apoptosis, remain bone-lining cells on the bone surface or become 
osteoclasts, cells encased and surrounded by bone matrix19,20. 
• Osteocytes: osteocytes are stellate cells characterized by a highly dynamic nature. They 
can remodel in response to physiologic functional forces, guiding the osteoclasts and 
osteoblasts for bone resorption and formation, respectively. The osteocyte cell size is 
decreased, the synthetic and secretory organelles are fewer and smaller than osteoblast 
ones, larger space is occupied by the nucleus but organelles capable for protein secretion 
are still present. Numerous and extensive cell processes ramify throughout the bone in 
canaliculi and make contact, frequently via gap junctions, with other osteocytes processes 
or with the ones extending from osteoblasts or bone-lining cells at the surface of the 
bone; in this way an essential network of communication is created among these cells, 
that could suffer from isolation considering the surrounding dense and mineralized 
matrix17,20. 
• Bone-lining cells: these cells cover the most quiescent bone surface in the adult skeleton 
and derived from the osteoblasts that undergo gradual morphological and functional 
changes, till the decrease of protein secretion. They can produce local regulatory 
substances and modify the composition of the underlying lamina limitans, playing a 
critical homeostatic role in compartmentalizing the bone matrix and influencing calcium 
and phosphate metabolism, important in the bone remodeling process. The hemostatic 
network, made by bone-lining cells and osteocyte processes, regulate plasma calcium 
concentration in the primary site of mineral ion exchange between blood and adult 
bone20.  
• Osteoclasts: large and multinucleated cells able to resorb bone in response to biological 
and functional regulatory factors. They support bony remodeling processes throughout 
life and mediate bone loss in pathologic conditions by increasing their resorptive activity. 
Osteoclasts are found on bony surfaces that undergo resorption, in shallow depressions 
called resorption bays (Howship's lacunae). Their action is mediated by the secretion 
of hydrochloric acid and proteases, such as cathepsin K, into an extracellular lysozomal 
compartment beneath a ruffled part of their basal cell membrane to dissolve the mineral 




The extracellular matrix has a composition like other bone tissues, even though the alveolar 
bone is a specialized structure with specific features and functions. The bone matrix primary 
components are interwoven collagen fibres with deposits of small and uniform carbonated 
hydroxyapatite (Ca10[PO4]6[OH]2) crystals. Other proteins, such as proteoglycans, acidic 
glycosylated and non-glycosylated proteins provide continuity between the matrix and 
cellular components and the matrix components themselves, regulating the formation of 
collagen fibres and inorganic crystals22.  
Calcium and phosphate in the form of carbonated apatite (or dahllite) are the predominant 
inorganic elements that replace the water of the soft, dense connective tissues, like 
periodontal ligament and gingiva. The organic matrix of bone serves most of the 
biomechanical function in housing the solid thanks to an ultrastructural organization. This 
complex structure, consisting of multi-rooted teeth within the alveolar bone, results able to 
stand the mastication and other unique forces within the oral cavity19.  
• Collagen: It is the major component in mineralized bone tissues. Type I and V collagens, 
with a percentage of 95 and 5% respectively, assemble the heterotypic fibre bundles 
responsible for the integrity of the connective tissues. In the alveolar bone, Type III 
collagen is also found mixed with the type I in Sharpey’s fibres, providing a connection 
with the tooth and probably preventing fibre’s mineralization. Besides, also type XII 
collagen is present and involved in the mechanical strain. Type I, V, XII collagens are 
produced by osteoblasts, while type III and some of type XII are expressed during the 
formation of the periodontal ligament by fibroblasts. Intermolecular cross-linking among 
the collagen fibrils can create a stable structure, providing high tensile strength in the 
fibres. In the woven (forming) bone, there is a vasty interfibrillar space occupied by 
mineral crystals since fibres are interwoven. In mature bone, fibres are arranged in layers 
oriented perpendicular to each other, with little interfibrillar space. In the space between 
the collagen molecules and channels formed among the regions, crystal formation and 
growth occur in both the bone19. 
• Noncollagenous proteins: These proteins could change in the various types of bones and 
show age-related differences in the amounts. Some of them, such as osteocalcin and bone 
sialoprotein, are essentially unique to mineralized tissues rather than osteonectin/ SPARC 
(secreted protein, acidic, rich in cysteine) and osteopontin that have a more general 
distribution. The osteocalcin represents the 15% of noncollagenous proteins in alveolar 
 
10 
bone and it owns a high affinity for mineral bone, attributable to the gla groups of the 
pro-osteocalcin. Osteopontin plays a role in cell adhesion and several extracellular matrix 
events involved in the integration between the newer and the older bones during the 
remodeling cycle. Other noncollagenous proteins secreted by bone cells and plasma-
derived proteins, like albumin, a2HS-glycoprotein, immunoglobulins, and matrix gla 
protein, are also distributed throughout the bone matrix and may compete and/or 
participate in mineralization processes. Some small proteoglycans such as chondroitin 
sulfate proteoglycans have specifically modified forms able to interact with mineral 
crystal through the acidic glycosaminoglycan side of chainsprocollagen peptides. Other 
proteins, such as thrombospondin, fibronectin and vironectin, can modulate cell 
attachment and the alkaline phosphatase14. 
Although fundamentally comparable to other bone tissues in the body, alveolar bone is 
subjected to continual and rapid remodeling associated with teeth eruption and subsequently 
the functional demands of mastication. Many normal and abnormal processes could cause 
alterations in maxillary and mandibular bone tissue, such as metabolic and systemic diseases 
or medical treatments17. The ability of alveolar bone to undergo rapid remodeling is also 
important for positional adaptation of the teeth but may be detrimental to the progression of 
some illness such as the periodontal disease23. This condition can produce noteworthy 
changes in alveolar bone proper, having significant effects on its function and the ability to 
repair18.  
When serious inflammations, like pulpitis, affect the tooth, significant alveolar bone loss may 
also occur13,18. Inflammation reactions might involve the periapical part of the root and the 
PDL adjacent to the apex, leading to an ischemic state and in nonviable and necrotic bone 
tissue. Untreated dental diseases result in osteolysis that inevitably leads to dental loss13.  
Besides, after tooth extraction, irreversible alveolar bone resorption always occurs, producing 
dimensional and structural alterations in the alveolar processes of the jaws24. Implant 
installation is the most common functional and aesthetic restoration procedure for missing 
teeth, but it depends on the quantity and quality of the maxillary or mandibular bone25. 
1.3 Alveolar ridge remodeling after tooth extraction 
A dental extraction (or avulsion) is a surgical procedure that involves the removal of a tooth 
from the dental alveolus (socket), the natural mandibular/maxillary bone cavity in which it is 
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placed. Extractions are performed when the tooth became unrestorable by conservative 
methods (e.g., root canal therapy, filling), both for pathological reasons and physical 
impediments. Severe tooth decay and acute or chronic alveolar infections, such as periapical 
abscess, are the most common reasons26,27. Other critical situations that could lead to the tooth 
extractions are severe gum diseases, such as the periodontal disease28 in which tooth 
supporting tissues and bone structures might be affected, or dental trauma29, frequently 
discussed as an etiological factor in the formation of an idiopathic bone cavity30.  
However, even though teeth extractions are common practices in oral surgery, they are often 
associated with several post-surgical complications, ranged from expected and predictable 
outcomes, such as bleeding, oedema, infections and alveolar osteitis31, to more severe and 
permanent ones32.  
After exodontia, a well-documented sequence of events brings to the alveolar healing. Indeed, 
immediately after the avulsion, the socket is filled by a blood clot that within 1 week is 
replaced by granulation tissue. Differently from skin wound healing, epithelial cells migrate 
over the granulation tissue surface to cover the healing socket because it is recognized as 
connective tissue. Starting from the apical and lateral residual bony walls, the granulation 
tissue is rapidly remodeled to provisional matrix; successively mineralizing processes occur, 
leading to the formation of woven bone that could be also replaced by mature lamellar bone33.  
Notwithstanding this, a lifelong, irreversible and cumulative three-dimensional bone 
resorption always occurs, mostly during the first year34. It starts in concomitance with the 
healing of the soft and hard tissue wound and continues also after the cessation of de novo 
bone formation into the socket35. The bundle bone appears to be the first bone to be rapidly 
absorbed and replaced with woven bone leading to a great reduction in bony height especially 
in the buccal aspect of the socket33.  
The amount of bone loss has been estimated at 21% after 3 months, 36% after 6 months, 44% 
after 12 months, and it seems to proceed at an average of 0.5-1% per year for the entire life34, 
resulting in the removal of large amounts of the jaw structure. This remodeling process leads 
to changes of ridge morphology, mostly in the horizontal dimension but also referred to the 
vertical ridge height. These changes have been widely described by study cast and 
cephalometric measurements, radiographic analysis and direct measurements of the ridge 
following surgical procedures36. The key factors cause of these phenomena are still under 
discussion. On the one hand, the resorption could be a natural consequence of bundle bone 
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uselessness after tooth removal but, on the other hand, this event could be related to the 
surgical trauma of the extraction that may imply the separation of the periosteum and its 
disconnection from the underlying bone surface. In the latter case, vascular damage and acute 
inflammatory response could occur, mediating bone tissue remodelling37. Moreover, local and 
systemic factors tent to influence the whole healing process and marked differences could 
also occur between the maxillary and mandible bone34.  
Though, even with uneventful healing following dental extractions, the wound in the 
extraction socket is only partially restored and alveolar bone resorption leads to the formation 
of vary-size bony defects36. These lesions could also occur as a consequence of periodontal 
disease if inflammation spreads from gingiva to alveolar bone, trauma, infection secondary to 
caries, or due to the development of cysts38,39 
Among all the replacement options, the dental implants are the most common, as well as 
extremely effective and long-lasting when successfully applied. Some studies report that 
implants placed immediately after tooth extraction have some advantages such as prevention 
of bone resorption, reduced number of surgical procedures, and reduction of comprehensive 
treatment time. However, this procedure is often associated with a residual bone defect 
between the neck of the implants and residual bone walls40. Favorable alveolar ridge 
architecture and adequate bony volume are essential factors to obtain optimal functional and 
aesthetic prosthetic reconstructions, thus there are anatomic, metabolic, functional and 
prosthetic criteria to evaluate, such as the quantity and quality of available bone for dental 
restoration36. 
1.4 Guided Bone Regeneration and Alveolar Ridge Preservation 
To prevent the development of severe bone resorption and provide an adequate bone height 
and width for successive implant rehabilitation, numerous surgical techniques have been 
proposed, such as the guided bone regeneration procedures (GBR) and the alveolar ridge 
preservation (ARP)41–43. 
The GBR techniques lead to lateral and vertical ridge augmentation, aiming to the 
reconstruction of alveolar bone defects and treatment of peri-implant bone deficiencies, often 
needed in the absence of ridge preservation; the APR treatments aim to the maintenance of 
horizontal and vertical ridge dimensions after extraction placing grafting material into the 
socket to prevent bone resorption and reduce dimensional changes44,45. 
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The final goals are33: 
• Reduction of alveolar bone volume loss. 
• Fast bone regeneration and restoration to provide adequate bone volume for implant 
placement. 
• Improvement of the aesthetic outcome of the final prosthesis.  
Hence, the rehabilitation of edentulism using osseointegrated implants is a restoration 
technique that has revolutionized the field of dental surgery and improved patients’ quality of 
life. 
GBR, based on the use of membranes and graft materials and aimed at the three-dimensional 
regeneration of alveolar bone defects33,46, has become a major treatment option to provide 
optimal bone support for osseointegrated dental implants. It is based on principles of guided 
tissue regeneration (GTR), developed by Nyman et al. in 1980, stating that specific cells 
contribute to the formation of specific tissues47. The concept of creating a separated anatomic 
site in which promote the healing was first introduced when cellulose acetate filters were 
experimentally used for the regeneration of nerves and tendons43. Thus, the biological 
rationale of GBR is based on the mechanical exclusion of undesirable soft tissues from 
growing into the osseous defect, allowing only osteogenic cell populations to repopulate the 
bony wound space43.  
GBR has been used for horizontal and vertical ridge augmentations, demonstrating reliable 
outcomes with high implant survival rates and low complication rates48. The regeneration 
procedures depend on the migration of pluripotential and osteogenic cells like osteoblasts to 
bone defect site and the exclusion of cells that obstruct bone formation, non-osteogenic tissue 
cells like fibroblast or epithelial cells. Osteoblasts could derive from the periosteum, bone 
marrow and adjacent bone45. Thereby, the barrier membranes are essential to refrain gingival 
cells from penetrating the defect that needs to be regenerated33.  
After GBR procedures, bone regeneration follows a specific sequence of events. Within the 
first 24 hours after the space underneath the barrier is filled with a blood clot able which 
releases growth factors (e.g., platelet-derived growth factor) and cytokines (e.g., IL-8) that 
attract macrophages and neutrophils. Granulation tissue, rich in new blood vessels, replaces 
the clot allowing nutrients and mesenchymal stem cells capable of osteogenic differentiation 
to reach the wound site. Woven bone, formed by the mineralization of osteoid, will be the 
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template for lamellar bone apposition45. The optimal healing is presumed to be achieved if the 
osteogenesis rate extending from adjacent bony margins exceed the fibrinogenesis rate from 
surrounding soft tissues. 
There are four principles to ensure successful GBR: space maintenance, the stability of the 
fibrin clot, primary wound closure and exclusion of epithelium and connective tissue49.  
The methods that can be used in GBR to enhance the rate of bone formation are the 
osteoinduction, by the use of appropriate growth factors, the osteoconduction, using grafting 
material as a scaffold for new bone growth, and the GTR, based on space maintenance by 
barrier membranes to be filled with new bone33,45.  
Hence, the GBR therapeutic protocol involves the surgical placement of a cell occlusive non-
resorbable and absorbable membrane facing the bone surface, to physically seal off the 
skeletal site in need for regeneration, with or without particulate bone grafts or/and bone 
substitutes and, more recently, bioactive molecules46. The membrane must show suitable 
characteristics such as biocompatibility, cell-occlusion properties, integration by the host 
tissues, clinical manageability, 
space-making ability, and adequate mechanical and physical properties48. 
Better clinical outcomes are achieved when membranes possess specific properties50: 
• Ability to exclude from the wound site the gingival fibroblasts or/and epithelial cells, to 
prevent the formation of fibrous connective tissue.  
• Size trimmed to extend about 2-3 mmm beyond all the defect margins so that space 
beneath it is created when applied; rounded corners prevent flap perforation. 
• Ability to protect the fibrin clot from the flap movement during healing to provide the 
suitable environment to the osteoprogenitor cells; often suture, mini bone screws or bone 
tracks are used to fix better the membrane.  
To support the membrane and prevent its collapse in fenestrations, bone-replacement grafts, 
serving as an internal framework, or stiffer membranes, such as titanium-reinforced 
membranes, could be used.  
An essential issue in GBR treatment is the membrane, that could be made of different 
materials or present different modifications48. Both non-resorbable and resorbable membrane 
materials, made by synthetic or natural polymers, have been used in the context of GBR 
treatment, clinically or experimentally43. 
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The most used non-resorbable barriers are the expanded polytetrafluoroethylene (E-PTFE) 
membranes, representing the first generation of membrane for GBR treatments. E-PTFE is a 
chemically stable and biologically inert polymer, resistant to microbiological and enzymatic 
degradation, with a porous and flexible structure and essential space-making capacity33,43,51. 
This membrane is the gold standard of GTR and GBR treatments and consisted of 2 parts: a 
collar portion, having open pores to allow in-growth of connective tissue and to prevent 
epithelial migration; and an occlusive portion, preventing the flap tissues from coming into 
contact with the root surface50. Dense-polytetrafluoroethylene (d-PTFE), titanium mesh and 
titanium-reinforced PTFE are other types of non-resorbable membranes commonly used in 
GBR procedures52. The major drawbacks in the use of non-resorbable membranes are their 
excessive rigidity and difficult manageability, the necessity of a primary fixation, the 
increased risk of exposure and increased risk of infection after exposure52.   
To overcome these issues, the second generation of membranes made by resorbable materials 
was developed and greatly appreciated by patients for the time and cost saved. Collagen type 
I, polyurethane, polyglactin 910, polyglycolic acid, polyorthoester, polylactic acid and 
different copolymers of polylactic acid are some of the biodegradable materials tested48. 
Surely collagen keeps the key role among these biomaterials since it is a major component of 
the bone, acts as a track on which cells can move50. Collagen is a haemostatic agent that can 
stimulate platelet attachment and enhance fibrin linkage, facilitating clot formation and 
stabilization. Furthermore, it is chemotactic for fibroblasts, easily manipulated and adapted 
and well tolerated50. 
The resorbable polymers undergo for stages of degradation once placed in an aqueous 
environment: hydration, strength loss, loss of mass integrity and solubilization via 
phagocytosis. Nature of polymer, pH, temperature, polymer crystallization degree and 
membrane volume govern the duration of each stage and the whole degradation rate. The 
main drawback is related to the high variability in membranes resorption that deeply 
influences bone regeneration and wound healing processes43.  
The placement of graft materials into a socket has been one of the ARP method proposed to 
prevent the natural tissue contours at extraction site42. Bone grafts substitute materials are also 
used in the GBR techniques, placing them underneath the membrane to provide structural 
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support, prevent membrane collapse, preserve the space, and enhance the regenerative 
capacities of the host tissues.  
Physical and chemical properties of graft materials, such as crystallinity, porosity, surface 
roughness granule size and morphology, influence the performances of the biomaterials from 
cells behaviour to the bone formation process, playing key roles on the osteointegration and 
osteoconduction processes. 
They are commonly classified in autograft, allograft, xenograft and alloplasts, depending on 
their origin, although the conventional bone regeneration techniques involve autologous 
grafts44.  
• Autograft: these types derive directly from the patients, whether oral or extraoral origin 
and play a key role in bone formation enhancing the osteogenesis by osteoinduction and 
osteoconduction processes. For ages considered the gold standard of bone grafts, the 
autograft mechanism is based on two components: the anatomical host site, that provides 
support for the cellular growth, and the Type I collagen which acts as a pathway for 
vascularity and neo-angiogenesis. Nevertheless, autogenous bone grafts present some 
drawbacks such as morbidity of the additional surgical site, limited graft accessibility risk 
of clinical complication, prolonged operation time and high cost of interventions45,50. 
• Allografts: they derive from individuals of the same species as the host, and are generally 
classified in frozen bone allograft, freeze-dried bone allograft (FDBA), and 
demineralized freeze-dried bone allograft (DFDBA). They could have the forms of 
putties, gels, or particulate (e.g., Puros Cancellous), ready-to-use without the necessity of 
a secondary surgical site. Although they are a source of type I collagen, they do not 
provide the bony inorganic calcium whether the scaffolding proprieties to support bone 
regeneration45,50. 
• Alloplasts: they are inert and synthetic graft materials; hydroxyapatite and calcium 
phosphate are some exponents of this group. They are used to endure the healing of bony 
defects and the mechanism of action is strictly osteoconduction. On account on their 
synthetic origin, they could have different chemical composition, physical forms, and 
surface configurations (porosity, densities, solubility) that play a key role in the variable 
level of bioresorbability45,50.  
• Xenografts: materials derived from other species, usually bovine or porcine, deprived of 
the organic components to avoid the immunological reactions in the host. Thus, they are 
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inorganic materials rich in calcium and acting as an architectural matrix, able to maintain 
the augmentation space during the regeneration process. The low resorption rate may 
negatively impact the healing of the grafted site and compromise the mechanical and 
biological properties of the regenerated bone45,50.  
Other components used as graft are the recombinant bone morphogenetic proteins (BMP), 
osteoinductive compounds, and the tissue-derived growth factors for osseous regeneration. 
About seven BMPs types have shown a speedup of the bone formation process, positively 
affecting several processes such as chemotaxis, proliferation, and differentiation50. 
A potential solution to provide more predictable results could be the use of bone inductive 
growth factors that may enhance the development of mature lamellar bone and possibly lead 
to earlier and more predictable support of dental implants53. 
1.5 Non-transfusional Hemocomponents 
In the last years, more reliable and predictable results in the field of regenerative medicine 
have been obtained using bone inductive growth factors, such as plasma-rich growth factor 
(PRGF).  
The use of blood-derived products on wounds to stimulate healing was first described 40 
years ago with the fibrin glues, based on concentrated fibrinogen. Nowadays, autologous 
fibrin is limitedly used due to the complexity and the cost of their production protocols, thus 
these products have been replaced by the use of platelet concentrates54. 
Platelet concentrates have been defined as an innovative approach for tissue regeneration, 
applied in various surgical fields including head and neck surgery, otolaryngology, 
cardiovascular surgery and, as mentioned before, maxillofacial surgery55.  
The dental and oral surgery applications range from ablative surgical procedures, mandibular 
reconstruction, and surgical repair of the alveolar cleft to procedures relating to the placement 
of osseointegrated implants, correlated to the management of post-extraction socket healing.  
Autologous platelets-concentrates contain high quantities of key growth factors and 
cytokines, such as platelet-derived growth factor (PDGF), transforming growth factor-beta 
(TGF-b), vascular endothelial growth factor (VEGF), and platelet-derived endothelial growth 
factor (PDEGF), that are released during the plasma-concentrate preparation56,57. These 
factors, also found in tissues during natural healing, have a crucial role in several cell events, 
like induction, proliferation, differentiation, chemotaxis, and synthesis of the extracellular 
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matrix that are linked to processes like mitosis, osteoblast proliferation, vascularization, and 
collagen synthesis56.  
The major effects of these systems are related to the PDGF, important protein for both hard- 
and soft-tissue healing, able to stimulate chemotaxis, mitogenesis and the replication of stem 
cells at the wound site. It also promotes the production of hyaluronic acid and fibronectin, a 
cell adhesion molecule important for cellular proliferation and migration during healing55,57.  
Moreover, TGF-b1 and TGF-b2 are also involved in connective tissue repair and bone 
regeneration since they can stimulate fibroblast, chemotaxis, the proliferation of mesenchymal 
stem cells and osteoblasts, and the production of collagen and fibronectin by cells, inhibiting 
collagen degradation by decreasing proteases and increasing protease inhibitors55,57.  
Thus, the use of platelet-concentrates rich in growth factors in APR and GBR techniques has 
been considered a promising and innovative strategy to achieve soft and hard tissue healing in 
the post-extraction sockets56,58,59 overcoming the drawbacks affecting the traditional 
procedures. It has been demonstrated that these systems could enhance alveolar bone 
preservation or regeneration by accelerating bone repair, promoting fibroblast proliferation, 
and increasing tissue vascularity in the alveolar sockets55,57. Improved clinical outcome in 
terms of percentages of success and reduction of bleeding, inflammation, pain, and 
discomfort, have been also obtained57. Moreover, plasma concentrates are autologous and 
easily obtained at a relatively affordable cost. They have also demonstrated promising results 
in the management of extensive periapical lesions, apicomarginal defects, and combined 
endo-perio lesions60. 
The first generation of blood-derivate products are called Platelet-rich-plasma (PRP) and are 
obtained by techniques variable in time but all based on collected blood with anticoagulant, 
just before or during surgery, immediately processed by centrifugation54.  
During the first soft-spin centrifugation step, blood is separated into three layers: red blood 
cells (RBCs) at the bottom, acellular plasma (platelet-poor plasma, PPP) as the supernatant 
and a ‘buffy coat’ (BC) layer where platelets are concentrated in between54 (Figure 2).  
The second step for the collection of the “bluffy coat” vary among the different protocols that 
allow the production of pure PRP (P-PRP) without leucocytes or leucocyte-rich PRP (L-PRP). 
These two systems production greatly depending on the means of BC collection (Figure 2)54. 
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• For P-PRP production, PPP and superficial BC are moved in another tube to undergo 
hard-spin centrifugation. Discarding most of the PPP layer, the final P-PRP concentrate is 
obtained and consists of an undetermined fraction of BC rich in platelets suspended in 
some fibrin-rich plasma but not in leucocytes (Step 2a)54,58. 
• For L-PRP production, PPP, the whole bluffy coat and some residual RBCs are 
transferred to another tube and undergo hard-spin centrifugation. The final L-PRP is 
obtained discarding the PPP and consists of the entire BC, rich in platelets and 
leucocytes58, and residual RBCs suspended in some fibrin-rich plasma (Step2b). 
 
 
Figure 2: Platelet-rich plasma protocol using a two-step centrifugation procedure. 
Finally, whichever is the final product, it is applied by a syringe to the surgical site, together 
with thrombin and/or calcium chloride (or similar factors) to trigger platelet activation and 
fibrin polymerization. 
The second generation of platelet-derivates has been developed by Choukroun et al. and are 
the platelet-rich fibrin (PRF), obtained from collected blood without any anticoagulant and 
immediately centrifuged27,61. The formation of leucocytes and platelet-rich fibrin (L-PRF) 
occurs following a natural coagulation process, that does not require biochemical 
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modification of the blood, any anticoagulant, thrombin, or calcium chloride. The easy and not 
expensive protocol is surely the advantages of this open-access technique61.  
A clear classification of platelet concentrates is possible following three main parameter 
sets54: 
The first is related to the preparation kits and centrifuge machine used. In particular, the 
centrifuge size, duration of the procedure, costs of kits and devices and procedure complexity 
are important factors, since they own a significant impact on the daily use of these surgical 
techniques. 
The second group of parameters relates to concentrating content. Indeed, the final volume of 
usable concentrate influence the potential clinical applications of the preparation protocol and 
deeply depends on the initial blood harvest. The efficiency in collecting platelets and 
leucocytes and their preservation during the process are the other three parameters that tend to 
influence the pharmacological relevance and potential applications of the products.  
The third set of parameters are related to the fibrin network supporting platelets and 
leucocytes concentrates during the application. Fibrin network density plays a key role and is 
mainly determined by fibrinogen concentration during preparation. Low-density fibrin 
networks allow convenient surgical application, but true fibrin support matrix is missing, 
while high-density ones could be considered as biomaterials owing potential healing effects 
itself.  
Another important parameter is the fibrin polymerization process that relates to fibrinogen 
and thrombin ratios, correlated to the biomechanical properties of the final fibrin network 
since thrombin actives fibrinogen which polymerizate into fibrin. Fibrin fibrillae can be 
organized in two biochemical architectures, either as condensed tetramolecular or bilateral 
junctions or as connected trimolecular or equilateral junctions. The former derives from a 
drastic activation and polymerization, that could happen with high thrombin concentrations 
that lead to the formation of a dense network of monofibres, not suitable for cytokine 
enmeshment and cellular migration. Instead, the equilateral junctions derived from a slow 
physiological polymerization that leads to the formation of a flexible fibrin network with 
multifibres, with elasticity similar to that of a solid biomaterial and able to provide the 




1.6 L-PRF and PRF-Block 
Leucocyte-and platelet-rich fibrin is the second generation of platelet concentrated, obtained 
by a simple and free technique developed in France by Choukroun et al.62 in 2001 without any 
anticoagulants or gelifying agents63.  
The protocol developed by ©2018 Intra-Lock International, the partner company of the PhD 
project, was followed to create the L-PRF and its derivate, the PRF-Block. 
This preparation method involves the collection of venous blood in a dry glass tube and the 
low-speed centrifugation during which, in absence of anticoagulants, fibrin polymerization 
and platelet activation are triggered immediately. Three layers are formed after centrifugation: 
the RBCs at the bottom of the tube, acellular plasma top layer (both discharged) and a PRF 
clot in the middle (figure 5)54,61. 
Both platelets and leucocytes are collected with high efficiency, preserving the leucocytes 
throughout the entire process and, platelet activation during the procedure leads to a 
substantial embedding of platelet and leukocyte growth factors into the fibrin matrix54,61,63.  
Indeed, the L-PRF clot is a strong fibrin matrix characterized by a complex three-dimensional 
architecture rich in platelet and leucocytes that, if pressed between two gauzes, could become 
a strong membrane (Figure 3) and widely applied as an autologous biomaterial in oral, 






Figure 3: L-PRF clot obtained from collected blood without anticoagulants and compressed to obtain L-PRF 
membrane.  
As the other platelets derivate, its use leads to an improvement of soft tissue healing63 and 
bone graft protection and remodeling but, in contrast with PRPs, PRF does not dissolve 
promptly once applied in the target site, instead it undergoes slowly remodeling like the 
natural blood clots54. 
The growth factors and cytokines are released from the L-PRF in a continuous and delayed 
manner, most significant in the early days but sustained up to 21 days64. Their action is 
mostly related to the regulation of the inflammatory process and increases angiogenesis, 
allowing speeding up the tissue healing process. Furthermore, fibrin-based scaffolds are 
considered biomaterials able to provide physical support for different cells such as 
neutrophils, macrophages and fibroblasts, which will produce collagen, fibronectin and other 
extracellular matrix components65. 
Several medical disciplines have used L-PRF in different types of surgery, including 
periodontology, implant dentistry, and maxillofacial surgery, reporting a positive effect for 
the wound healing process. Actually, L-PRF dense plugs or membranes can be adapted to 
several tissue defects, as in case of post-extraction sockets and have been used in ARP and, 
recently, in GBR procedure30,56,66,67. 
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Several studies on alveolar sockets preservation have underlined that sockets treated with L-
PRF as “sole” grafting exhibited a faster wound healing after tooth extraction, compared to 
the natural and spontaneous healing and similar results in ARP as other bone substitutes, with 
several advantages such as simplified procedures, less post-operatory pain and inflammation, 
the absence of residual graft particles, and the benefit of its low cost58,59. 
The fast epithelization of alveolar soft tissue might also reduce the possibility of 
complications, such as osteitis and postoperative pain, and the preservation of alveolar bone 
may promote osseointegration and improving implant stability, leading to reliable and 
successful functional restoration by implants67.    
An interesting L-PRF derivate is the Platelet Rich Fibrin Block (PRF block), obtained 
combining L-PRF membranes, Liquid Fibrinogen and bone graft materials, and 
resulting in a strong construct of fibrin integrating the bone substitute65 (Figure 4).  
 
 
Figure 4: A) L-PRF clot; B) PRF-Block 
This putty form of L-PRF is obtained mixing the cut L-PRF membranes and the graft 
materials with Liquid fibrinogen, that acts as a clotting accelerator for the L-PRF/Biomaterial. 
The adaptation and healing qualities of the bone graft will be enhanced by its hydration with 
the L-PRF compression exudate, that helps create the desired putty-like consistency. In this 
way, the biomaterial is captured in the fibrin matrix and coagulated using the liquid 
fibrinogen, increasing the biomaterials handling & biologic capacity.  
Although the PRF-Block has a recent development, it has already exhibited promising results 






into the defect site, that after could be closed by L-PRF membranes66. The promising aspect 
of PRF is based on the combination of the xenograft, acting as a scaffold with 
osteoconductive ability, and the L-PRF membranes serving as a bioactive nodule with 
osteoinductive capacity65.  
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b) Technological approach for tissue regeneration 
Factors such as microbial infections, presence of excessive free radicals and reduction in 
antioxidant-based scavenging systems cause serious challenges by prolonging inflammation 
and delaying bone repair processes68. For these grounds, the employment of scaffold or 
nanocomposite enriched with antimicrobic and antioxidant agents is considered as a 
promising tool for bone regeneration bioengineering. 
As mentioned above, resorption of the alveolar ridges and consequently bone loss is in both 
vertical and horizontal dimensions always occur after tooth extraction. However, bone 
remodeling and reabsorption can also occur before teeth extraction, as a consequence of oral 
diseases as periapical pathology, periodontal disease or trauma to teeth and bone36,69. In some 
of these conditions, one of the major causes for delay or failure in the bone restoration process 
is the infection, thus the use of antibiotics could improve the bone healing process70. 
Metronidazole (MTZ) is an antibiotic from the nitro-5-imidazole family used in the 
periodontal disease treatment since its action against anaerobic organisms, strongly associated 
with the damage of periodontal tissue70 (Figure 5). However, its systemic administration is 
associated to several side effects, such as hypersensitivity and gastrointestinal intolerance, 
drawbacks related to the gastrointestinal tract, such as diarrhoea, nausea, vomiting, and 
pseudomembranous colitis and its prolonged use tent to increase the risk to develop a 
bacterial resistance71,72. 
 
Figure 5: MTZ chemical structure 
Bone reabsorption could be also promoted by an overproduction of reactive oxygen species 
(ROS) and, subsequently, oxidative stress not balanced by antioxidants. The main 
consequences are a reduction of the wound healing process and altered bone metabolism due 
to increased differentiation of preosteoclasts in osteoclasts73. Thus, bone recovery could 
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benefit from the use of antioxidant agents such as Curcumin (CUR), a polyphenolic 
compound known for a wide variety of biological activities such as antioxidant, antimicrobial, 
anti-inflammatory, anti-arthritic and chemopreventive properties commonly applied in 
dentistry74,75 (Figure 6).  
 
Figure 6: CUR chemical structure 
It has been demonstrated that a topical administration of CUR in the post-extraction socket 
right after the surgical treatment can decrease soft tissue inflammation, can protect the wound 
from bacterial infections, increase collagen deposition and stimulate cell proliferation, 
improving tissue regeneration76. However, CUR is characterized from an extreme lipophilic 
nature and physicochemical instability, thus it needs to be loaded into the pharmaceutical 
formulation to be available in aqueous environment77, and among the numerous carrier 
strategies,  lipid-based colloidal dispersions seems to be suitable to overcome the problems of 
degradation, poor solubility, and penetration inside the tissue78,79. 
In the last years, the interest in lipid nanoparticulate systems has increased mainly due to their 
versatile nature as controlled release systems for lipophilic compounds.  
The nanoscale dimensions associated with a large surface to volume ratio, comparable to 
peptides and small proteins, allow nanoparticles diffusing across membranes and facilitate 
uptake by cells, mimic the natural nanometer size scale of the extracellular matrix (ECM) 
components80. Since classic engineered materials used in tissue engineering are not always 
able to mimic the natural properties of the target tissue and to overcome this drawback, the 
development of customized nanoparticles could be a solution.  
The first generation of lipid nanoparticles is represented by the solid lipid nanoparticles 
(SLNs), developed in early 1990 to match the advantages of colloidal systems with high 
biocompatibility and the biodegradability of the lipid constituents. The SLN preparation 
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requires the use of a single solid lipid and surfactants, that could vary from soy lecithin, 
polysorbates to Pluronic. 
The advantages of using SLN as modified release systems are numerous81: 
• Ability to control drug release 
• Increased drug stability 
• A decrease in the volume of drug distribution 
• Absence of carrier toxicity 
• Absence of organic solvents in the preparation phase 
• Possibility of large-scale production and sterilization 
• A wide spectrum of applications 
• Possibility of active targeting functionalizing the surface.  
However, SLN main drawback is the low drug loading capacity, related to the tendency to 
expel it over time and attributable to the uni-lipid composition of SLNs. Indeed, the lipid tents 
to undergo polymorphic transitions, from metastable to stable form till the formation of highly 
ordered structure, that means the decreasing of  available space for the entrapped substances, 
which are expelled82. 
A natural evolution of SLNs is represented by nanostructured lipid carriers (NLC), the new 
generation of lipid nanoparticles developed to overcome the loading problems associated with 




Figure 7: Differences between SLNs and NLCs83 
NLCs are composed of a mixture of biocompatible and biodegradable liquid and solid lipids 
with short and long chains, mainly mono-, di- and triacylglycerides, fatty acids and waxes, 
that provides the system the ability to load great amounts of drug since the system is 
composed of an amorphous and highly disordered structure. Moreover, the imperfect 
architecture of the lipid matrix plays a key role in the controlled release phenomena, owed to 
the slowly and gradually phase transition that lipids undergo once in contact with the 
mucosae, that allow avoiding the burst effect typical of SLN83. 
Recently, sponges, defined as a dispersion of gas in a solid matrix with a porous structure, 
have been developed as an innovative formulation for the design of wound dressing and 
transmucosal drug delivery systems. They are prepared by removing water from a polymer 
matrix by a freeze-drying procedure to obtain a solid, dried, soft, and flexible structure in 
which NLCs could also be entrapped84–86, obtaining a nanocomposite biomaterials. 
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In the light of previous considerations, the use of both antioxidant and antimicrobial agents 
could be an interesting approach to enhance bone preservation or restoration in the post-
extraction socket. Thus, an innovative and promising strategy could be the development of 
multi-composite biomaterials and scaffolds consisting of sponges loaded with antimicrobial 
agents and nanostructured lipid carriers containing lipophilic antioxidant, to be applied in 
association with the L-PRF and deliver the actives on surgical sites of teeth extractions. This 
innovative approach could promote ridge preservation, prevent bone reabsorption and support 
bone regeneration87.  
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Aim of the PhD thesis 
This PhD thesis is based on a project cohering with the National Operational Program (PON) 
“Research and Innovation” (R&I) 2014-2020 funding by the Italian Ministry of Education, 
University and Research. 
The project is focused on the development and promotion of Regenerative Medicine to 
improve the oral health-related quality of life of patients in need of implant-based 
rehabilitation after tooth extraction. As part of this program, the aim of this thesis was the 
validation of an innovative protocol for the Guided Bone Regeneration using the second 
generation of autologous platelet concentrate, the Leukocytes and Platelet-rich Fibrin (L-
PRF), to prevent alveolar bone resorption and promote bone regeneration in the post-
extraction sockets. 
The L-PRF was obtained following the ©2018 Intra-Lock International protocol, thus 
withdrawing and processing the patient’s blood, and has been applied in the post-extraction 
sockets as L-PRF membrane or PRF-Block. Their ability to prevent alveolar bone resorption 
and ridge dimension variations and to promote soft tissue healing and bone regeneration in 
size-variable bony defects were evaluated.   
This innovative procedure has been developed to overcome the drawbacks related to the 
conventional GBR procedures, based on the use of external membranes and bone substituted 
from different sources and it is founded on the know-how of the partner company in 
standardizing the preparation method of L-PRF and PRF-Block combining with the expertise 
of oral surgeons of the University of Palermo.  
The interest in the use of L-PRF and PRF-Block in bone regeneration is constantly arising 
among the oral researchers, but, since it has been only recently investigated, the collected 
results are still limited. Within this context, the outcomes achieved by this study appear to be 
in line with contemporary literature proving an added value at the same. 
Moreover, several complications can occur after dental avulsions due to the establishment of 
local inflammatory processes, as well as the onset of microbial infections, mainly generated 
by bacteria Gram-negative. 
Thus, the secondary aim of this PhD thesis was the development and the characterization of a 
nanocomposite biomaterial consisting of a hyaluronate-based sponge loaded with 
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metronidazole (MTR) and nanostructured lipid carriers containing curcumin (CUR-NLC) able 
to release the actives on post-extractive socket.  
Indeed, curcumin is a natural compound owing interesting properties, such as antioxidant, 
anti-inflammatory and antibacterial, but it is characterized by pronounced lipophilicity, poor 
solubility in aqueous media and high environment chemical instability. Thus, to promote the 
absorption of this poorly soluble active ingredient through the tissues of the oral cavity, 
suitable nanostructured lipid carriers have been designed as delivery system. 
Furthermore, bacteriological studies have shown that most forms of periodontal disease are 
infections caused by excessive growth of a limited number of Gram-negative and anaerobic 
microorganisms and Metronidazole is the ideal antibiotic for these types of infections. 
Since this nanocomposite has been designed to be applied wrapped in the L-PRF membrane, 
minitablets need to be prepared, to obtain standard systems with suitable dimensions for the 
post-extraction sockets. 
The application of this innovative system after tooth extraction may be able to promote the 
process of tissue regeneration due to the anti-inflammatory and antioxidant properties of 
Curcumin, and the antibacterial properties of Metronidazole, supporting and enhancing L-





Materials and Methods  
a) Leucocytes and Platelet rich Fibrin(L-PRF) for Guided Bone Regeneration 
 and Alveolar Ridge Preservation 
2.1 Patients characteristics 
This study was designed to evaluate the outcomes of solo L-PRF and L-PRF and PRF-Block 
in patients in need of bone augmentation or preservation before implant placements.  
A total of 15 patients in need of tooth extraction in the mandible or maxilla and schedule for 
future implant rehabilitation were enrolled at the Unit of Oral Medicine of the University 
Hospital (Policlinico Paolo Giaccone, Palermo) between May 2018 and May 2020. 
The study adhered to the principles described in the Declaration of Helsinki and began after 
the approval by Ethics Committee of the University Hospital “Policlinico Paolo Giaccone” in 
Palermo (approval number 09/2018).  
Before the surgical practices, all patients were informed of the study's procedures/ objectives 
and signed written informed consent.  
The patients were divided into two groups, depending on type of lesion, and required 
treatment.  
GBR group: Five patients were treated by GBR techniques after dental avulsion to regenerate 
three-dimensional bone defects, often attributable to vast periapical cysts; one patient was 
affected by a critical-size bone defect. L-PRF and PRF-Block were used in combination in all 
the surgical treatments.   
ARP Group: Ten patients were treated by ARP procedures to prevent alveolar bone 
resorption, in need of tooth extractions for excessive dental mobility due to extensive caries 
with endodontic/periapical involvement. Only L-PRF was used in five of those patients; L-
PRF and PRF-Block were used for the remaining ones. 








Table 1: Patient characteristics 



























2.2 Inclusion and exclusion criteria 
The patients fulfilled the following inclusion criteria:  
➢ older than 18 years 
➢ no medical history that contraindicates the surgical procedure 
➢ healthy or with systemic disorders (e.g., diabetes mellitus, clotting and osteometabolic 
disorders) suffering from horizontal, vertical, or combined bone atrophies  
➢ healthy or with systemic disorders (e.g., diabetes mellitus, clotting and osteometabolic 
disorders) requiring oral surgery to remove dentary elements in bone inclusion or 
maxillary bone cysts and contextual regenerative bone procedures and with a high risk of 
post-operative complications  
A patient was excluded in the presence of any of the following contraindication: 
• pregnancy 
• heavy smokers (  15 cigarettes die) 
• under antiresorptive therapy (as bisphosphonates) for more than 3 years 
• cancer disease and radiant therapy of the head-neck district 
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• conditions as decompensated diabetes, decompensated metabolic and hematologic 
diseases and ASA IV patients.  
2.3 Preparation of L-PRF and PRF-Block 
Before the beginning of the surgical procedures, L-PRF and PRF block were prepared 
according to the techniques described by Dohan et al. (2009)54 and Cortellini et al. (2018)66 
and the Intra-lock protocol. The whole preparation is shown in figure 8. 
Protocol for preparation of L-PRF  
• Collection of 8 tubes of venous blood (about 10 ml each) from patients; withdraws must 
be carried out as quickly as possible because no anticoagulant is present in the tube and 
blood starts to clot in about 2 minutes. Two tubes with the white cap and glass coating 
(WCT; IntraSpin™, Intra-Lock, FL, USA) and 6 tubes with the red cap and plastic coated 
(BVBCTP2; IntraSpin™, Intra-Lock, FL, USA) were used. 
• Centrifugation in the IntraSpin™ system (ISS220 Intra-Lock, FL, USA) at 2700 rpm.  
• After 3 minutes, interrupt the centrifugation to remove the two white cap tubes.  
• Immediately restart the centrifuge with red cap tubes for other 9 minutes. 
• Aspirate with a sterile syringe the Liquid Fibrinogen (PLyF), the yellow supernatant of 
white cup tubes, getting as close as possible to the red cells being attention to not aspirate 
them. 
• After full centrifugation, three layers were formed in the red cap tubes: a base of red 
blood cells at the bottom, acellular plasma on the top (supernatant), and a clot of PRF 
between them.  
• Withdraw the L-PRF clots by sterile tweezers and isolated from the RBCs. 
• Discard the RBCs and PPP. 
• Obtain the L-PRF membrane moving the clots on the grill of the Xpression Box 
(IntraSpin™, Intra-Lock, FL, USA) and press for about 5 minutes.  







Preparation of “block” 
• Chop from two to three L-PRF membranes into small pieces and mix in Ti-dish to 0.5 g 
of β-tri-Calcium phosphate (Sint-Oss, Industrie Biomediche e Farmaceutiche srl, SA, 
Italy) (50:50 ratio). 
• Add L-PRF exudate if the mix is too dry. 
• Spray 1cc of liquid fibrinogen and stir gently for ±10 s and shape to obtain a 
homogeneous complex with the desired form. 
• The activated platelets of the chopped membranes let fibrinogen to polymerize into fibrin 




Figure 8: L-PRF and PRF-Block preparation: A) Blood collection; B) Red cup tube; C) L-PRF clot formation 
after 12 min centrifugation at 2700 rpm; D) Clots on the grill of the Xpression Box; E) G) L-PRF membranes; 
H) White cup tube; I) J) PRF-Block formation; K) L) PRF-Block. 
2.4 Treatment procedures 
To assess the absolute requirement for the dental extraction, all the patients underwent clinical 
examination, intraoral radiographs and, when required, computer tomography scan 
(CT/CBCT).  
These assessments allowed evaluating the alveolar bone conditions and the presence and 
dimensions of bony lesions, defining the need for GBR or ARP procedures.  
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When necessary, antibiotics (amoxicillin + clavulanic acid 500/125 mg) were prescribed for 7 
days. 
Before exodontia, a periodontal treatment, based on plaque control and supra and subgingival 
scaling, was performed on all the participants, that also received 30mL of chlorhexidine 0.2% 
mouthwash to swish up for 60 s. Then, local anesthesia was achieved using 3% mepivacaine 
hydrochloride with adrenaline. 
2.5 GBR procedures 
• Performance of a full-thickness midcrestal incision between the teeth preserving the 
interdental papilla and two full-thickness vertical incisions down to the bone on either 
side. 
• Elevation of a full thickness mucoperiosteal flap. 
• For teeth in need of extraction, tooth luxation and extraction, gently performed with 
elevators and forceps and minimally traumatic procedure. 
• Removal of cysts when present and debridement of the post-extraction sockets from 
granulation tissue, performed by miller surgical curette (Figure 10a, b). 
• Cortical perforations made with a round bur in the buccal cortex. 
• Performance of perioplastic surgery.  
• Application of L-PRF clot under the sinus floor and L-PRF block in the bone lesion and 
post-extraction sockets (Figure 10c). 
• Application of the remaining L-PRF clots over the surgical site (Figure 10d, e). 
• Tension-free soft tissue closure (Figure 10f). 
• Removal of suture after 7-10 days.  
2.6 ARP procedures 
• Dental luxation and extraction performed with elevators and forceps with minimally 
traumatic procedure.  
• Revision of the socket and irrigation with sterile saline solution. 
• Application of just L-PRF or L-PRF block in the alveolus. 
• Application L-PRF membrane clots over the surgical site. 
• Graft stabilization by sutures.   
• Removal of suture after 7-10 days. 
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2.8 Postoperative control, follow-up, and implant placement 
Analgesics (600 mg ibuprofen) were prescribed every 6 h in case of pain. In the following 
weeks, patients were under strict oral hygiene measures and were seen for the postoperative 
appointments at seven-ten to value the presence of infections or swelling and the healing of 
the soft tissue. Further controls were assessed after one, three and six months.  
In case of uneventful tissue healings and when require, implant placement was performed six 
months after the exodontia. The gums were sewed shut over the implant, and sutures were 
removed after 7-10 days. When required, above all in patients presenting periapical cysts, 
alveolar bone samples were collected using trephine bar before implant surgery.  
Three months after the placement, clinical and radiographic evaluations and implant retained 
provisional restorations were performed. The definitive implants were loaded after about two 
months once bone tissue regeneration was achieved and estimated as well as implant 
osteointegration in de novo bone. 
2.9 Clinical measurements 
Once sutures have been removed, 7-10 days after extraction treatment, the aspect of soft 
tissue was evaluated. 
The soft tissue healing was assessed based on modified healing index of Landry et al67. The 
parameters used to assess the level of healing were the color of tissue, the epithelialization of 
wound margins, the presence of bleeding on palpation, and granulation.  
Following these criteria, the healing level was scored as very poor, poor, good, very good, or 
excellent (Table 2). This evaluation was performed by an experienced professional and 









Table 2 Criteria (Landry et al., 1998) for the soft tissue healing assessment. 





























bleeding bleeding no bleeding no bleeding no bleeding 
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2.10 Radiographic measurements 
Bone healing, augmentation and regeneration were determined by radiographic measurements 
considering the variations in bone volume and density. 
Dental radiographs and cone-beam computed tomography (CBCT) were acquired pre-
operatively to value the eventual presence and size of cysts and six months after treatment to 
confirm the bone regeneration following GRB procedures and the maintenance of the 
adequate bone volume as results of ARP treatments. 
Besides, a dental radiograph was also performed three months after implant placement to 
verify the osteointegration and implants parameters, such as absence of radiolucent interface 
between bone and implant and peri-implant bone loss, have been also valued.  
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b) Technological approach for tissue regeneration 
2.11 Materials 
Curcumin was purchased from Alfa Aesar (Karlsruhe, Germany), isopropyl palmitate (IP), 
glycyrrhetic acid (GA), sodium hyaluronate (HyNa), and metronidazole from A.C.E.F S.p.a. 
(Fiorenzuola d’Arda, Italia) and Isopropyl myristate (IM) and Polysorbate 20 from 
Farmalabor, Canosa di Puglia, Italy. 1-hexadecanol (HEXA), Tween 80 (Tw80), Pluronic F-
68 (P-68), and polyvinylpyrrolidone (PVP-K90) were from Sigma Aldrich (Saint Louis, MO, 
USA), and Trehalose dihydrate (TRH) from la Hayashibara Shoji (Okayama Japan).  
Citrate buffer 10 mM (pH 6.2) was obtained dissolving 2.675 g of sodium citrate dehydrate 
and 0.190 g of citric acid monohydrate in 1 L of distilled water.  
Non-enzymatic artificial plasma pH 7.4 (PBS) was prepared dissolving 2.80 g of KH2PO4 and 
20.5 g of Na2HPO4 in1 L of distilled water, with or without the 4% of Polysorbate 20. 
Buffer pH 6.8 solution simulating saliva was prepared using NaCl (0.126 g), KCl (0.937 g), 
NaHCO3 (0.631 g), KSCN (0.655 g), KH2PO4 (0.2 g), Urea (0.2 g), Na2SO4 (0.154 g), NH4Cl 
(0.178 g), CaCl2 (0.130 g), and NaHCO3 (0.631 g) in distilled water; 0.9% saline solution was 
prepared by dissolving 9 g of NaCl in 1 L of distilled water. 
All chemicals and solvents of analytical grade were purchased from VWR International 
(Milano, Italy) and used without further purification.  
2.12 Lipid ratio mixtures screening studies  
Lipid mixtures (LM) made by HEXA, IP, and GA were prepared changing both the ratio of 
the components and CUR (Table 5). 50 or 80 mg of CUR were added under stirring to 950 or 
920 mg of pre-heated at 70°C LM by a silicon bath on a hot plate (Heidolph MR2001 K 
equipped with EKT 3001 electronic temperature control, Germany) and samples were 
maintained in these conditions for one hour. The lipid mixture considered good was cooled at 
room temperature and finally stored at 2-4°C until the subsequent use. After 24 hours, the 
melting point of the mixture was evaluated (Büchi Melting Point B-540). The analysis was 





2.13 Preparation of CUR-Loaded NLC and CUR-Loaded NLC Dispersion Enriched in 
Metronidazole 
MIX7 was chosen to prepare the CUR loaded NLCs, by the homogenization followed by 
probe sonication method. Briefly, 20 mL of 10 mM citrate buffer pH 6.2 containing 1% (w/v) 
Tw80 and/or 1% (w/v) F-68, previously brought to 90 °C, were added to the melted lipid 
mixture (100, 200, or 300 mg) and firstly homogenized at 30,000 rpm (Polytron Model PT 
MR 2100, Kinematica, Switzerland) for 1 min and then sonicated by an ultrasonic 
homogenizer SONOPULS (Bandelin, mod. HD 2070) for 10 min in pulsatile mode with 
cycles of 0.7 s of activity and 0.3 s of inactivity. Then an additional ultrasonic treatment of 10 
min was carried out, placing the container in an ice bath. The compositions of the prepared 
NLCs are given in Table 6. 
M7-300-TP dispersion was chosen for the next step. 150 mg of MTZ were solubilized in 20 
mL of hot 10 mM citrate buffer pH 6.2 containing the surfactants before the CUR-NLC 
preparation. Therefore, the CUR-NLC with MTR dispersion (CURNLC-MTR) was prepared 
in the same way as previously described. 
2.14 Characterization of Nanostructured Lipid Carriers 
2.14.1 Particle Size, Polydispersity Index, and Zeta Potential Analysis 
The mean particle size, the polydispersity index (PI), and the zeta potential (ZP) were 
determined by dynamic light scattering (DLS) using a Nano-ZS Zetasizer (Malvern 
Instruments, Worcestershire, UK). All experiments were performed at 25 °C under an 
electrical field of 40 V7 cm for ZP analyses on the day NLCs were prepared. The results of all 
NLCs analyzed are reported in Table 7.  
2.14.2 Morphology by Scanning Electron Microscopy (SEM) and Transmission Electron 
Microscopy (TEM) 
To evaluate the morphology and the topographic characteristics of both CURNLC-MTR and 
CUR-NLC dispersions, SEM analyses were performed. Measurements were carried out using 
a scanning electron microscope (Zeiss EVO MA10, Oberkochen Germany) equipped with an 
SE-Everhart-Thornley secondary electron detector with lanthanum hexaboride (LaB6) 
cathode as the source of electrons, an accelerating voltage of 20 keV and probe voltage of 10 
pA and the scanning electron microphotographs were acquired in high-vacuum condition and 
magnified up to 50.000 (200 nm). 
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Few drops of fresh CUR-NLC dispersion were put on an aluminum stub, placed in a CaCl2 
desiccator at 8°C for 24 h, and then coated with an ultrathin layer of gold (thickness about 2 
nm), to increase the surface electrical conductivity. For the samples of sponges loaded with 
MTR and CUR-NLC, a gold coating was applied before each analysis. 
For the TEM measurements, one drop of diluted CUR-NLCs and CURNLC-MTR was placed 
on a carbon-coated 200 mesh copper grids for 5 min and negatively stained with 1% uranyl 
acetate solution before being allowed to dry, and the samples were visualized by using a 
JEOL JEM-1011 microscope (JEOL Ltd., Tokyo, Japan) equipped with a tungsten thermionic 
gun operating at 100 kV accelerating voltage. The TEM images were acquired with an 11 
MPx Orius 1000 CCD camera (Gatan, Pleasanton, CA, USA). 
2.14.3 Entrapment Efficacy (EE) of NLC 
The total amounts of CUR and MTR in the fresh NLC dispersion were determined by UV-
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𝐃𝐫𝐮𝐠 𝐢𝐧 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 
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Then, entrapment efficacy (EE) and loading capacity (LC) of NLCs were indirectly 
determined by quantification of free CUR (unentrapped) in the aqueous medium, applying 





𝐂𝐔𝐑 𝐢𝐧 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 −  𝐟𝐫𝐞𝐞 𝐂𝐔𝐑 
𝐂𝐔𝐑 𝐢𝐧 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 







𝑪𝑼𝑹 𝒊𝒏 𝒇𝒐𝒓𝒎𝒖𝒍𝒂𝒕𝒊𝒐𝒏 −  𝒇𝒓𝒆𝒆 𝑪𝑼𝑹
𝑳𝒊𝒑𝒊𝒅𝒔 𝒂𝒎𝒐𝒖𝒏𝒕
× 𝟏𝟎𝟎    (𝟑) 
 
 
To evaluate the concentration of the unentrapped drug in the aqueous medium, two methods 
were chosen: 
(a) Dialysis assay: dialysis tube (molecular weight cut o_, MWCO, 12–14000 Daltons, 
Visking Dialysis Membrane—Medicell Membranes Ltd., London, UK) was pre-activated, 
filled by 1 mL of NLC dispersion, and submerged in 350 mL of distilled water, keeping it 
protected from the light at room temperature and under gentle magnetic stirring. After 24 h, 
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both the dispersion inside the tube and the external aqueous phase were analyzed by UV-Vis 
analysis. 
(b) Ultrafiltration assay: 0.45 mL of fresh NLC dispersion were placed in the upper chamber 
of a centrifugal filter tube (Ultrafree-MC, Millipore, cut-o_ 10,000 NMWL, and 30,000 
NMWL) and then centrifuged (Microfuge 22R, Beckman coulter., Brea, CA, USA) at 8000 
rpm at 4°C for 30 min. The aqueous solution collected at the bottom of the tube was subjected 
to UV-Vis analysis to determine the free CUR content89. 
2.15 Preparation of Sponges Loaded with Metronidazole and Curcumin Nanostructured 
Lipid Carriers 
Two gels differing in composition were prepared:  
• HyNa 2.50 g, PVP-K90 0.40 g, and TRH 15.0 g in 100 mL of water  
• HyNa 4.0 g, PVP-K90 0.60 g, and TRH 10.0 g in 100 mL of water 
An aliquot of 2 or 4 g of gel was added to the M7-300-TP or the M7-300-TP-MTR fresh 
dispersion, and the whole mixture was ultrasonically homogenized for 10 min with cycles of 
0.7 s of activity and 0.3 s of inactivity by placing the container in an ice bath. The sample was 
frozen at -80°C for 24 h, and then moved to the freeze-drier (Labconco FreeZone® Kansas 
City, MO, USA 2.5 Liter Freeze Dry System), setting the vacuum at 0.014 mPa and -54°C of 
temperature and maintaining these conditions for 48 h. Sponge-C-MTR was the sample 
chosen for the next characterizations.  
2.16 Porosity  
The freeze-drying process allows removing the solvent from the formulation to obtain a porous 
structure, with air in the space previously occupied by the solvent. The sponge porosity, meant 
as total pore volume, was calculated mathematically according the following equation (5) 90: 
%𝑷𝒐𝒓𝒐𝒔𝒊𝒕𝒚 =
𝒑𝒓𝒂𝒄𝒕𝒊𝒄𝒂𝒍 𝒗𝒐𝒍𝒖𝒎𝒆 − 𝒕𝒉𝒆𝒐𝒓𝒆𝒕𝒊𝒄𝒂𝒍 𝒗𝒐𝒍𝒖𝒎𝒆
𝒑𝒓𝒂𝒕𝒊𝒄𝒂𝒍 𝒗𝒐𝒍𝒖𝒎𝒆
× 𝟏𝟎𝟎         (𝟓) 
 
 
As theoretical volume was considered the bulk volume of the total ingredients of one sample 
and was calculated according to the equation (6): 
𝑻𝒉𝒆𝒐𝒓𝒆𝒕𝒊𝒄𝒂𝒍 𝒗𝒐𝒍𝒖𝒎𝒆 =  
𝒎𝒏
𝝆𝒏
          𝟔  
 
Where m and ρ are respectively mass and density of each ingredient.  
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The practical volume of sponge was determined placing the sample in a graduated cylinder and 
measuring the occupied volume (length x width x height)  
2.17 Hygroscopic Measurement of Sponges 
The ability of sponges to attract water molecules from the atmospheric moisture at room 
temperature was evaluated using an analytical balance (mod. AE 240, Mettler-Toledo S.p.A., 
Milan, Italy). Before each test, a desiccant box containing silica, was kept in the weighing 
chamber for 15 min. 
Immediately after exiting the freeze dryer, an aliquot of sponge was weighed, and after the 
two side doors of balance were opened, allowing the sponge to contact the environmental 
moisture. At intervals of 10 min, the weight of the sponge was recorded prolonging the 
experiment until the powder showed no increase in weight. The increase in weight of each 
sample was calculated as follows (7): 
𝐖𝐞𝐢𝐠𝐡𝐭 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞 % =
𝑾𝒕 − 𝑾𝒊
𝑾𝒊
 𝒙 𝟏𝟎𝟎       (𝟕) 
 
 
where Wt is the weight of sponge at time t, and Wi is the weight of dry sponge.  
2.18 Quantitative Determination of CUR and MTR in the Sponges 
A total of 5 mg of the lyophilized sponge was placed in a 20 mL flask, brought to volume 
with methanol, and sonicated until complete dissolution. Then, 1 mL aliquots were 
centrifuged (15,000 rpm for 2 min), and the supernatant was spectrophotometrically analyzed. 
The analysis was carried out on three aliquots from each lyophilized sponge. 
2.19 Preparation of Minitablets 
To standardize the sponge amount for the next analyses, minitablets were produced by 
compressing a precisely weighed amount (30 mg) of Sponge-C-MTR. A graduated mould 
having 5 mm diameter as well as a mobile upper and a lower plunger was used, obtaining a 
minitablet with a volume of 0.76 cm3. 
2.20 Swelling Test 
Weight and optic assessments were used to perform the swelling tests on the minitablets. 
The weight tests were carried out, weighting the minitablets by an analytical balance (Mettler, 
Columbus, OH, USA, Mod. AE 240). 0.5 mL of artificial saliva (pH 6.8) were added on the 
tables very 5 min for 20 min. At each timepoint, the excess water was removed with a filter 
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paper, and the weight was assessed. Tests were performed on six different minitablets, and 
results were reckoned following the Equation (8). 
𝐒𝐰𝐞𝐥𝐥𝐢𝐧𝐠 𝐈𝐧𝐝𝐞𝐱 =





           (𝟖) 
 
where Wt is the weight of the minitablets at time t, and W0 is the weight of the dry sample. 
The optical assays were performed with both the plan and the frontal assessments. Samples 
were previously placed on a microscope slide and then on graph paper. Every 5 min for 2 h, 
0.5 mL of simulated saliva (pH 6.8, 37°C) were added, and photographs were taken to 
evaluate any change on the minitablets’ morphology. 
2.21 Ex Vivo Permeation/Penetration Studies of CUR and MTR from Minitablets 
through L-PRF Membrane 
The L-PRF membranes were prepared following the IntraLock protocol, previously described, 
and approved by the Food and Drug Administration (FDA). 
The L-PRF membranes were fixed between the two compartments of the jacketed Franz type 
diffusion cells to perform the ex vivo permeation/penetration studies of CUR and MTR from 
minitablets. The donor chamber was filled by the minitablet and 0.5 mL of citrate buffer pH 
6.2, while the citrate buffer pH 6.2 plus 4% (w/v) of Tween 20 was used as receiver fluids. 
The experiments were carried out on 3 h, withdrawing 0.5 mL every 5 min, replacing the 
same volume with fresh fluid, and keeping the system temperature at 37 ± 0.5 °C. At the end 
of each experiment, the amounts of CUR and MTR entrapped inside the L-PRF membrane 
were quantified by the extraction in methanol (3  3 mL). The extracted liquors were 
collected, transferred in a 10 mL flask, and brought to volume with methanol.  
2.22 MTT Cell Viability Assay  
Homo sapiens bone marrow stromal cells (HS5) were grown in DMEM (ATCC® 30-2002) 
added with 10% fetal bovine serum (FBS) and antibiotics and maintained in culture in a 
humidified incubator under 5% CO2 and 95% air at 37 °C. HS5 cells were seeded at 30.000 
cells/cm2 and, the day after, the medium was removed and substituted with fresh medium 
containing different concentrations of the empty nanocomposite sponge (without CUR and 
MTR), or Sponge-C-MTR. The following concentrations were tested: 0.025 mg/mL, 0.0502 
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mg/mL, 0.080 mg/mL, 0.12 mg/mL and 0.15mg/mL. MTT assay (Invitrogen M6494) was used 
to evaluate cell viability at 24 hours after the treatment. 
2.23 Drugs Quantification by UV-Vis Methods 
The amounts of CUR and MTR entrapped in the NLC suspension, the sponges, and the 
membranes were measured spectrophotometrically (UV-Vis mod. Pharma Spec 1700, 
Shimadzu, Tokyo, Japan) using the appropriate calibration curve and blank. The linearity was 
statistically determined by regression analysis of five concentrations in the range below 
specified and evaluated in triplicate. UV-Vis methods were found as simple, accurate, and 
reproducible. 
For CUR determination, two calibration curves in methanol were performed at λmax = 428 
nm: in the linearity range of 0.0002-0.0075 mg/mL, regression equation was Abs = -0.0289 + 
132 x [mg/mL] (R = 0.999, SE 0.0101) and in the linearity range of 0.0025-0.01 mg/mL, 
regression equation was Abs = -0.0108 + 136 x [mg/mL] (R = 0.997, SE 0.0397).  
For the calibration curve in phosphate buffer pH 6.2 plus tween 20 (4% w/v) in the linearity 
range of 0.0001-0.001 mg/mL, the regression equation was Abs = 0.01277+160 x [mg/mL] (R 
= 0.997, SE 0.0105).  
For MTR determination were found validation parameters in methanol, in PBS and in 
Phosphate buffer pH 6.2 plus tween 20 (8% w/v), at λmax = 310 nm. For PBS, linearity range 
was 0.0025–0.0125 mg/mL, regression equation Abs = 0.0011 + 61.78 x [mg/mL] (R = 0.999, 
SE 0.0040). For Phosphate buffer pH 6.2 plus tween 20 (8% w/v), linearity range was 
0.0025–0.02 mg/mL, regression equation Abs = 0.0771+ 46.8 x [mg/mL] (R = 0.998, SE 
0.0102). Finally, for methanol, linearity range was 0.0025–0.03 mg/mL and regression 
equation Abs = 0.0011+ 62 x [mg/mL] (R = 0.999, SE 0.0092). 
2.24 Data Analysis 
Data were expressed as mean ± SE of at least three replicates (n = 3). For the statistical 




CHAPTER 3  
Results 
a) Leucocytes and Platelet rich Fibrin(L-PRF) for Guided Bone Regeneration 
 and Alveolar Ridge Preservation   
Fifth-teen patients aged between 29 and 70 (mean 49.4) years, including 9 females and 6 
males completed the study. Each patient had tooth extractions, treatment of post extraction 
socket with L-PRF alone or in combination with PRF-Block and implant placement as 
rehabilitation approach.   
3.1 GBR treatment 
Five patients presented horizontal and/or vertical bone defects, mostly due to periapical cysts, 
thus GBRs were performed to augment the bone volume. Results and further information are 
shown in table 3.  
Table 3: Results of GBR Treatments  
PATIENTS 1 2 3 4 5 
AGE 33 45 55 51 45 
GENDER M F M F F 
TEETH RELATED TO 
THE BONE DEFECT 












SMOKER No No Heavy No No 
SOFT TISSUE HEALING 
INDEX AFTER 7-10 
DAYS 
4 3 3 2 3 
BONE REGENERATION 
AFTER 6 MONTHS 
Yes Yes Yes Yes Yes 
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IMPLANT PLACEMENT Yes Yes Yes Yes Yes 
Radiological and clinical examinations after the treatment showed the integration of the grafts 
with the surrounding bone.  
All patients showed uneventful postoperative wound healing, without adverse events. After 6 
months from the GBR treatments, all patients showed evident bone regeneration and adequate 
bone volume for implant placement. Three months after implant insertion, radiographic 
evaluations showed a suitable osteointegration achieved in all the placed implants.  
Patient 5 presented a lesion that led to critical-size defect formation. The GBR treatment 
performed on this lesion is reported as case report 1. 
 
3.2 ARP Treatment 
Ten patients were treated to prevent the resorption of alveolar ridges; five of them needed the 
exodontia due to the severe mobility of interested teeth ascribable to periodontal disease, 
while the others presented small cysts close to tooth roots. Results and further information are 
shown in table 4.  
Table 4 Results of ARP Treatments 
PATIENTS 1 2 3 4 5 6 7 8 9 10 
AGE 45 55 70 55 48 38 59 68 29 45 
GENDER M M F F F F M M F F 
EXTRACTED 
TOOTH 






























































Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
IMPLANT 
PLACEMENT 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 
Radiological and clinical examinations after the treatment showed the integration of the grafts 
with the surrounding bone.  
All patients showed uneventful postoperative wound healing, without adverse events. After 3-
4 months from the ARP treatments, all patients showed slight and irrelevant changes in 
alveolar ridge dimensions, providing adequate bone volume for implant placement. Three 
months after implant placement, radiographic evaluations showed a suitable osteointegration 
achieved in all the placed implants.  
Patient 5 underwent extraction due to the fractur of the anterior tooth; the ARP treatment 
performed on this extraction socket is reported as case report 2. 
 
3.3 Case reports 
3.3.1 Case 1– Guided bone regeneration of a critical-size alveolar bone defect 
A non-smoker 45-years old woman complained a right-side facial pain and swelling, begun 
some days before the first clinical examination, that revealed abnormal mobility of teeth #14-
16, previously endodontically treated, and pain response to percussion testing. There was no 
significant systemic complaint. The family history was unremarkable.  
The dental radiographs showed the presence of a large cystic lesion referred to the mentioned 
teeth (Figure 9a). Thus, a CBCT with a multiplanar reconstruction program (MPR) was 
assessed to evaluate the three-dimensions of the lesion, showing a periapical lesion 
approximately 20 mm x 15mm x 14mm, with a soft, fluctuant, and cystic consistency, 
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resulting in a critical-size alveolar bone defect (Figure 9b, c, d). The final diagnosis was 
odontogenic cyst and teeth #14-16 with hopeless prognosis. Based on the findings, teeth 
extraction, cyst removal and GBR procedures combined with L-PRF and L-PRF block were 
planned (Figure 10). 
Before the beginning of the surgical procedures, L-PRF and PRF block were prepared 
according to the techniques described in Material and Method section, as well as GBR 
surgery was performed following the protocol exposed in material and method section.  
Histological examination confirmed the odontogenic nature of the cyst (i.e., 
periapical/radicular cyst) and in the following weeks, the patient was under strict oral hygiene 
measures and on regular recall. Soft tissue healing was uneventfully, no infection or swelling 
after the surgery. Bone tissue healing was observed with dental radiograph six months 
postoperatively (Figure 11a, b). 
The second stage surgery, implant placement, was then performed and before the procedure 
an alveolar bone sample was obtained from the #15 implant site using a trephine bur (Figure 
11c.). Three implants (Blossom, Intra-lock, USA) were placed in the area of teeth #14-16 
(Figure 11d, e, f). The sample was processed and bone histomorphometry was performed 
(Figure 11g). Sutures were removed after 10 days. 
Three months after implant placement, an impression was made; implants were loaded with 
screw-retained temporary fixed partial restorations. Definitive restoration was placed after 2 
months (Figure 12a). The regeneration of bone tissue was highlighted with a new CBCT 
(Figure 11b, c, d). 
The histological analysis showed that the L-PRF block was able to produce mature alveolar 
bone tissue, achieving the bone healing in about six months. The regenerated bone structure 
allowed the subsequent implant prosthetic rehabilitation; two months after their placements, 




Figure 9: radiological examinations.  a) detail of the dental radiograph at the first clinical examination; b) c) d) 
3D CBCT scan before surgery. 
 
Figure 10: a) bone defect after dental extractions and cyst removal; b) cystic lesion; c) application of L-PRF clot 
under the sinus floor and L-PRF block in the bone lesion and post-extraction sockets; d) e) application of the 




Figure 11: a) b) Six months post-surgical regeneration procedures, clinical and radiological view; c) bone sample 
harvesting procedure at the #15 implant site using a trephine bur; d) dental implants placement; e) f) intraoral 
radiograph after placing dental implants; g) magnification of histological findings of the bone sample 
(osteoblastic cells on the surface of the new woven bone containing osteocytes. 
 




3.3.2 Case 2 –Alveolar Ridge Preservation in a post extraction socket  
A non-smoker 48-years-old female presented to our attention with a suspected fracture of the 
upper right central incisor (Figure 13a, b, c, d).  Anamnestically, the patient reported no health 
concern and no consumption of tobacco or alcohol, and the family history was unremarkable. 
The patient presented an orthodontic splint of upper anterior teeth, placed by a colleague to 
avoid tooth crown loss. Radiological examination confirmed the tooth fracture of the #11. 
The severe mobility of the anchored fragment and root led to its extraction (Figure 13e) 
followed by the ARP procedure to prevent the ridge remodeling and alveolar bone resorption. 
L-PRF clots were applied, until the post extractive socket was completely filled (Figure 13f, 
g) and sutured to be stabilized (Figure 13h). The tooth crown was adapted on the previous 
orthodontic splint. Post-surgical antiseptic therapy has been prescribed to the patient. During 
the following weeks, the patient was under strict oral hygiene measures and on regular recall 
and soft tissue healing was achieved uneventfully.  
After 3 months, the patient performed a Computed tomography (CT) dental scan. The 
clinical-radiological evaluations showed the presence of adequate and ample bone ridge 
(Figure 14a, b); thus, the implant placement was planned and performed (Figure 14c) and 
later the implant was successfully loaded. 





Figure 13: a) fracture of the upper right central incisor; b) c) d) root and crown fragments; e) post-extraction 
socket; f) g) application of L-PRF clots filling the alveolus; h) sutures. 
 




b) Technological approach for tissue regeneration 
3.4 Lipid ratio mixtures screening studies  
The screening results obtained by visual inspection upon heating showed that none of the lipid 
mixtures in the tested ratios were able to solubilize CUR in an amount corresponding to 8% 
(w/w) of the whole mix. On the contrary, 5% CUR was completely solubilized when GA was 
present at 3%, and HEXA and IP were in 60:40 ratio (Table 5). The melting point of the 
MIX7 resulted in 48 ± 2 °C. 
Table 5: Composition of lipid mixtures. 
SAMPLE CUR (g) GA (g) HEXA (g) IP (g) HEXA: IP Appearance 
MIX 1 0.08 0.10 0.49 0.33 60:40 Opalescent 
MIX 2 0.08 0.10 0.41 0.41 50:50 Opalescent 
MIX 3 0.05 0.10 0.51 0.34 60:40 Opalescent 
MIX4 0.05 0.10 0.425 0.425 50:50 Opalescent 
MIX 5 0.08 0.03 0.53 0.36 60:40 Opalescent 
MIX 6 0.08 0.03 0.445 0.445 50:50 Opalescent 
MIX 7 0.05 0.03 0.55 0.37 60:40 Clear 
CUR: curcumin; GA: glycyrrhetic acid; HEXA: 1-hexadecanol; IP: isopropyl palmitate 
3.5 Preparation of CUR-Loaded NLC Dispersion Enriched in Metronidazole 
MIX7 was chosen to prepare the CUR loaded NLCs, that were obtained by homogenization 
followed by probe sonication method. To avoid the pH-dependent CUR decomposition91, the 
pH 6.2 citrate buffer was chosen as aqueous medium. All the NLC dispersions obtained by 
changing both the lipid mixture ratios and the surfactants (Table 6) were homogeneous, 
stable, and easy to re-disperse. 
Table 6: Composition of prepared NLCs using 20 mL of aqueous medium. 
SAMPLE AMOUNT OF MIX7 (mg) TW80 (mg) F-68 (mg) 
M7-100-T 100 200 - 
M7-200-T 200 200 - 
M7-300-T 300 200 - 
M7-100-TP 100 200 200 
M7-200-TP 200 200 200 
M7-300-TP 300 200 200 
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3.6 Characterization of Nanostructured Lipid Carriers 
3.6.1 Particle Size, Polydispersity Index, and Zeta Potential Analysis 
DLS measurements of nanoparticle mean particle size (Z-average), particle size distribution 
(PDI), and electrical charge (Z-potential, ζ) were performed to investigate the stability of the 
NLC dispersions and choose the one with the best parameters. Table 7 shows Z-average, PDI, 
and Z-potential values of all the studied formulations. According to these results, M7-300-TP 
was chosen to prepare subsequent formulations. 
Table 7: Mean particle size (Z-average), particle size distribution (PDI), and electrical charge surface (ZP) of 
NLC formulations. Values are expressed as mean ± SD (n = 3). 
Samples Z-Average (nm) PDI Z-Potential (mV) 
M7-100-T 121.8± 15.44 0.372 −20.5 ± 6.8 
M7-100-TP 117.9 ± 32.81 0.290 −19.5 ± 5.1 
M7-200-T 88.5 ± 8.68 0.733 −19.5 ± 6.44 
M7-200-TP 182.2 ± 36.88 0.265 −13.5 ± 7.95 
M7-300-T 689.4 ± 17.08 0.709 −20.5 ± 5.87 
M7-300-TP 157.0 ± 25.52 0.403 −25.5 ± 7.79 
M7-300-TP-MTR 112.0 ± 28.56 0.337 −24.0 ± 5.32 
3.6.2 Morphology by Scanning Electron Microscopy (SEM) and Transmission Electron 
Microscopy (TEM) 
To confirm NLCs shape and size as well as to investigate their surface morphology, the 
electron microscopy scan (SEM) was performed on M7-300-TP-MTR, and the micrographs 
are shown in Figure 15a. The nanoparticles appeared with spherical and smooth shapes, and 
the sizes were less than 200 nm; moreover, no crystalline structures of MTR were observed.  
In Figure 15b are reported TEM images of single NLCs loaded only with CUR and CUR-
MTR. As can be noticed, the detail of the single NLCs shows an average size of 50 ± 10 nm 





Figure 15: SEM morphology of dried dispersion M7-300-TP-MTR; bar = 200 nm. (b): TEM image of single 
NLC from M7-300-TP-MTR batch; bar = 50 nm. 
3.6.3 Entrapment Efficacy (EE) of NLC 
Preliminarily, the amount of CUR and MTR in the fresh NLC dispersion, expressed in terms 
of DR, was determined to evaluate the amount of active and inactive ingredients lost during 
the preparation step. CUR and MTR recovery (DR) was calculated using the effective volume 
of the fresh NLCs dispersion recovered, resulting in 93 ± 1.63% and 88 ± 2.04% (mean ± 
SE), respectively. Entrapment efficacy (EE%) and loading capacity (LC%) of NLCs were 
indirectly determined by quantification of the free CUR in the aqueous phase (unentrapped) 
by both dialysis and ultrafiltration methods. Since no free CUR was detected by both the 
analyses, the EE and the LC resulted respectively in 100% and 5% of recovered materials. 
3.7 Sponges Loaded with MTR and CUR-NLCs Formulation and Characterization 
Different samples were obtained changing the amount of gel used and they are reported in 
Table 8.  
All the samples appeared solid, friable, and uniform in color after drying, but an alteration of 
Sponge-A and Sponge-A-MTR occurred once in contact with the environmental temperature 
and moisture. In fact, when they were taken out of the freeze dryer, they became brown and 






Table 8: Nanocomposite sponge compositions. 
 COMPOSITION OF EACH BATCH OF COMPOSITE SPONGES (MG) 
 CUR-NLC MTR HyNa PVP-K90 TRH Tw80 P-68 Buffer Salts 




150 50 8 300 200 200 57 




150 100 16 600 200 200 57 




150 160 24 400 200 200 57 
The ability of the sponges to take up moisture from their surroundings were evaluated as 
weight increase over time. The solid-state of the samples was ensured during the experiment, 
to exclude potential transformations once the moisture was absorbed. In Figure 16 was 
reported the gradual increase of the weight up to 30 min. At this time, a plateau was observed, 
suggesting that the equilibrium with environmental moisture was reached. Based on these 
results, the less hygroscopic sponges were chosen for next characterizations.  
 
Figure 16: Percent of weight increase of sponges maintained in environmental moisture over time. Data 
represent mean ± SE (n = 3). 
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The amount of the active compounds was evaluated by analyzing different portions of powder 
of the same batch and quantifying the drugs by UV-Vis analysis. CUR and MTR resulted in 
0.9 ± 0.03% and 9.5 ± 0.02% w/w, respectively, showing a homogeneous distribution of 
active compounds in the whole samples.  
The structure and the morphology of sponges were investigated, as well as the porosity of 
Sponge-C and Sponge-C-MTR, that resulted in 93.15 ± 0.14% and 92.86 ± 0.18%, 
respectively.  
The porous nature of Sponge-C-MTR was confirmed by SEM images (Figure 17). The porous 
structure was plainly visible, with pores having an average diameter of about 10–20 μm. 
However, higher resolving power of SEM damaged the sample, thus the presence of NLC 




Figure 17: SEM images of surface morphology and internal structure of Sponge-C-MTR. (A) magnitude bar = 
20 µm; (B) magnitude bar = 10 µm. 
3.8 Preparation of Minitablets 
Afterwards, minitablets were obtained by compacting definite amounts of Sponge-C-MTR 
until a definite volume (Figure 18). Average tablet weight, diameter, and thickness resulted in 
30 ± 1.2 mg, 4.5 ± 0.05 mm, and 2.5 ± 0.05 mm, respectively. 
 




3.9 Swelling Test 
The maximum swelling degree was reached after 15 min, corresponding to a 2.7-fold increase 
of the initial weight, due to saliva absorption by minitablet forming a viscous gel layer around 
it. Figure 19 shows minitablet weight variations expressed as the increase in the initial weight 
versus time. 
 
Figure 19: Swelling index measured as weight increase versus time. Data are presented as means ± SE. 
The swelling aptitude of the minitablets was also evaluated by frontal and radial visual 
assessments (Figure 20). In both assessments, a partial loss of weight and dissolution occurred 
in 120 min. 
  
Figure 20: Timeline from 0 to 120 min of radial and frontal swelling of the minitablet. 
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3.10 Ex Vivo Permeation/Penetration Studies of CUR and MTR from Minitablets 
through L-PRF Membrane 
The ability of the minitablet to promote CUR and MTR permeation rather than penetration in 
the L-PRF clot was evaluated mounting L-PRF clot as a membrane in Franz type diffusion 
cells and applying minitablet to the apical side.  
No CUR was detected in the acceptor compartment, while the results of MTR amounts 
permeated in the acceptor chamber versus time are shown in Figure 21. The extrapolated flux 
(Js) per unit area of MTR through the L-PRF membrane resulted in 0.457 mg/cm2h. 
  
Figure 21: Permeation data of MTR per cm2 throughout the L-PRF membrane and linear fitting at the steady-
state concentrations. Values are presented as means ± SE (n = 6). 
The amounts of CUR and MTR accumulated in the L-PRF membrane at the end of each 
experiment (Figure 22) were evaluated by methanol extraction. The extracted CUR and MTR, 
expressed as a percent of the dose administered, resulted in 1.76% w/w and 2.5% w/w, 
respectively.  
 
Figure 22: L-PRF membranes before after permeation tests. 
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3.11 MTT Cell Viability Assay  
The MTT assay was performed after 24h incubation using a concentration range of 0.025-
0.15 mg/ml. Cell viability was almost not affected by the Sponge-C-MTR, resulting in 80-
90% referred to untreated control cells for the whole concentration range analyzed. On the 
other hand, the treatment with any concentration of the empty sponge led to viability between 





Figure 23: Cell viability of HS5 cells after 24h of treatment at different concentrations of the empty 
nanocomposite sponge or Sponge-C-MTR, compared to the cell viability of untreated cells (CN). Results are the 





a) Leucocytes and Platelet rich Fibrin(L-PRF) for Guided Bone Regeneration 
 and Alveolar Ridge Preservation   
The study aimed to evaluate the effect of L-PRF in its pure form and as L-PRF block in 
socket wound healing after tooth extraction as noticed by soft tissue healing, increased bone 
fill, and reduced alveolar bone width resorption allowing reliable implant prosthetic 
rehabilitation.  
Exodontia is one of the most common oral surgery procedures, indispensable when no other 
endodontic or preservative treatments can be used. Though, patients could undergo post-
operative discomfort and complications that could significantly affect the oral health-related 
quality of life. Hence, the achievement of a better-quality life for patients after the tooth 
extraction procedures is still a challenging goal for oral surgeries and researchers.  
The lack of one or more dental elements is often restored by implant placement, allowing 
appreciable functional and aesthetic rehabilitation. However, the conditio sine qua non to 
achieve reliable and long-lasting outcomes is the presence of adequate bone volume and ridge 
dimensions in the placement site. Widely strategies have been developed to rehabilitate 
deficiencies in bone volume occurring after tooth extraction, due to the natural ridge 
dimension remodeling and alveolar bone resorption, or in case of bony lesions. In particular, 
different GBR and ARP techniques have been proposed to regenerate bone defects or prevent 
bone resorption. Among graft materials currently used in oral procedures, autologous bone 
blocks have been often described as the gold standard. However, despite the proven success 
of these substitutes, they present some shortcomings such as the need for a second oral 
surgical site that, especially if outside the oral cavity, is related to higher patient morbidity 
and discomfort which can adversely affect the clinical outcomes as well as the quality of 
life92. Differently, in the case of the allografts, the main issues are related to their quality 
control, that has a direct impact on the clinical outcomes since disease transmission and 
infection control is of high significance, due to the cadaverous nature of these grafts93.  
Anyway, the use of grafts for socket preservation increases the treatment cost as well as the 
risk of disease decline and since they could not be totally incorporated into the newly formed, 
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they tend to show limited vital bone formation27. These drawbacks lead to increase the 
attention of clinicians in the selection of the type of graft that minimizes the adverse effects. 
The application of Non-Transfusional Hemocomponents as graft substitutes in oral surgery 
has been proposed with heterogeneous results.  
The use of platelet aggregates for the management of postoperative pain and discomfort, as 
well as the rapid healing of the soft and hard tissues of the post extraction socket, has been 
recently proposed as a reliable and popular alternative55,57,94. Besides, the role of L-PRF, the 
second-generation of platelets concentrated, in these processes has been lately 
investigated95,96.  
In the present study, the soft tissue recovery has been examined using the healing index 
system described by Landry et al. (1998)97. Once sutures were removed, after 7-10 days, 
comparable healing of the soft tissues was achieved both in GBR and ARP groups. These 
results are in accordance with a recent study by Mourão et al. in 202067, where better healing 
was observed in the sockets that received L-PRF when compared to the sockets with 
spontaneous healing, highlighting that the use of L-PRF should be considered whenever 
improved healing is required.  
Different mechanisms can be associated with soft tissue rehabilitation procedures based on L-
PRF application. The recruitment and stimulated proliferation of several cell types, including 
fibroblasts, and the promotion of collagen synthesis has been shown to be related to the 
released growth factors by in vitro studies98,99. The clotting activation, essential event to 
enhance the haemostasias, is favored by the cytokines found in L-PRF67,100. The formation of 
a fibrin matrix with a complex trimolecular structure that offers greater resistance, elasticity, 
and resembling a natural matrix is attributable to fibrinogen and thrombin, that are 
concentrated in this platelet aggregate. The stimulation of chemotaxis, angiogenesis, 
proliferation, differentiation, and modulation, especially in the early stages of healing, by the 
released growth factors and cytokines is plentifully supported. 
The ability of L-PRF to reduce post-operative pain, swelling and enhance the soft tissue 
healing seems to be experimentally and clinically supported, while the action on bone tissue 
regeneration is still controversial.  
In this study, the use of L-PRF alone or in combination with the PRF-Block for alveolar bone 
regeneration or preservation led to interesting results. In GBR group, adequate horizontal 
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ridge augmentations were achieved in all the patients affected by bony defects. In ARP group, 
the use of L-PRF as a filling material for socket preservation seemed promising in order to 
maintain an adequate volume of soft and hard tissues and obtain aesthetic rehabilitations. 
In all cases, bone volumes allowed implant-based rehabilitation within six months and a 
suitable osteointegration, critical factor for the long-term success and stability of implants, 
was achieved in all the implants three months after their placement.  
As regards the case report 1, to our knowledge, this was the first case regarding the 
application of L-PRF and L-PRF block for the management of large cystic removal and 
extraction of three teeth. 
L-PRF played a key role in remineralization, already significant six-months after the 
application. Although one standard definition for a critical-sized defect is not available, 
alveolar bone defects measuring 2-3 cm in diameter usually heal in about 12 months101,102. In 
our case, the bone healing was achieved in about six months, moreover, our histological 
analysis showed that the L-PRF and PRF block were able to produce mature alveolar bone 
tissue. These results could be related to L-PRF strong architecture, composed of micropores 
and thin fibres that allows it to serve as a scaffold for osteogenesis cell migration, 
differentiation and neovascularization, keeping the slow release of growth factors, as 
mentioned above, up to a period of 7-14 or 21 days54,61. Moreover, the preservation of bone 
ridges and the enhancement of the newborn formation could also be attributable to PRF-
Block, that might be considered as a biomaterial for tissue engineering65, since formed by 
biocompatible bone graft material processed with L-PRF membranes and fixed with liquid 
fibrinogen. In PRF block, the L-PRF acts as a biological connector among the graft particles, 
creating a matrix with suitable manipulative qualities and rich in bioactive molecules and 
growth factors54,64,103,104. Indeed, if it is well-known that xenografts can support osteoblast 
attachment and proliferation, several in vitro studies concluded that these effects can be 
further enhanced when PDGF is on their surface, indicating that growth factors on/or near to 
the xenografts might influence osteogenesis in vivo105,106. 
The stimulation of chemotaxis, angiogenesis, proliferation, differentiation, and modulation, 
especially in the early stages of healing, by the released growth factors and cytokines, is 
plentifully supported. The release kinetics of growth factors and cytokines from L-PRF and 
PRF-block have been also investigated. According to Lourenco et al., 2018, these substances 
are highly expressed with the 24h from L-PRF membrane, leading to an initial release that 
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may improve the clot formation and stabilization in the socket and have a role in the 
enhancement of the healing process. Besides, after the pronounced release in the first 24h, the 
release of these substances from the L-PRF membrane continues for up to 21 days100. While, 
in a study presented by Castro et al., 2019, a continuous release of growth factors from both 
L-PRF membrane and Block have been verified up to 14 days, even though the amount of 
growth factors was not the same. Indeed, the L- PRF exudate and the Liquid Fibrinogen 
embedded in the Block seemed to act as bioactive agents, affecting the release of growth 
factors, especially for levels per time interval of VEGF and BMP-1, while the L-PRF 
membrane seems to produce a higher concentration of TGF-β1 and three times more PDGF-
AB than the L-PRF block65.  
However, the interesting healing profile of PRF block has been only recently investigated and 
just few authors have reported its use in human oral surgeries (about 26 intervention on 15 
cases)59,103,107, even though promising results have been collected. In a single cohort 
observational study, Cortellini et al. performed 15 bone augmentation procedures on 10 
patients (mean age 50.7 years) affected by horizontal bone defects. The surgical procedures 
were based on the application of L-PRF block (a combination of two L-PRF membranes, 0.5 
g deproteinized bovine bone mineral and liquid fibrinogen), collagen membrane and L-PRF 
membranes. A significant horizontal ridge augmentation was achieved, allowing implant 
placement in all cases103. Chenchev et al. evaluated the possibility for augmentation of the 
alveolar ridge in the frontal region of the upper jaw in an 18-year-old male applying a 
combination of bone graft materials, injectable platelet-rich-fibrin (i-PRF) and advanced 
platelet-rich fibrin (A-PRF). This augmentation procedure was a successful and the dental 
implant was placed107. Andrade et al. published a pilot clinical study on four patients, they 
applied a “dentin block” (a mixture of particulate autologous dentin with chopped L-PRF 
membranes, and liquid fibrinogen) in ten extraction sockets. The “dentin block” was able to 
promote new bone formation, without host tissue reactions, and a favorable dentin 
resorption/bone formation rate. All patients demonstrated an adequate amount and quality of 
bone for implant placement59.  
Despite the limitations related to the use of an innovative procedure, the obtained positive 
outcomes in terms of bone healing and tissue regeneration were in accordance with the 





b) Technological approach for tissue regeneration 
CUR possesses extremely low aqueous solubility in both neutral and acidic pHs, with a 
reported value of 11 ng/mL in aqueous pH 5.0 buffer solution, while it is soluble in ethanol, 
methanol, and acetone108. Moreover, a rapid CUR decomposition in neutral-basic pH 
conditions is well known109. On the other hand, due to its poor solubility and high instability 
in aqueous fluids, CUR is an excellent candidate for the development of formulations using 
nanoparticle lipid systems110. 
In the pharmaceutical field, nano-encapsulation is highly exploited to promote the absorption 
of substances that, as such, would not cross biological membranes. Therefore, using natural 
and/or synthetic materials is possible to obtain formulations suitable also for CUR 
administration. The physicochemical characteristics of lipid materials, such as lipid 
miscibility, polymorphism, and stability, as well as the surfactant effect on structure and type 
of nanoparticles are the most relevant parameters to take into account in NLC formulation111. 
Moreover, among all the lipid materials, those that do not undergo light or heat degradation, 
or oxidation processes must be chosen. From the biological point of view, the excipients used 
for NLCs must be non-carcinogenic or teratogenic, non-allergenic, and removed from the 
body through the physiological metabolic processes. Since the biocompatibility of all the 
components with the biological tissues is necessary, and considering the lipid nature of the 
active ingredient, the choice fell on 1-Hexadecanol (HEXA), isopropyl palmitate (IP), and 18-
β glycyrrhetic acid (GA). 
HEXA is a long-chain fatty alcohol widely used in cosmetic products, possessing emollient 
properties and weak antimicrobial activity112. IP is a branched and low molecular weight 
liquid ester owing emollient characteristics, suitable solvent capacity for lipophilic active 
ingredients and easily absorbed. GA is an active triterpenoid metabolite of glycyrrhizin 
extracted from the dried roots and rhizomes of Glycyrrhiza glabra, existing as α and β stereo-
isomeric forms113. This well-known compound shows beneficial effects as skin whitening and 
anti-inflammatory agents in acute and chronic dermatitis, reducing skin lesion sizes and 
antioxidant activity against b-carotene destruction and LDL) oxidation114. Furthermore, 
antiviral, antibacterial, antifungal, antitussive, anti-diabetic, anti-diuretic, anti-ulcer, 
antihepatotoxic, cytoprotective, and cytotoxic effects were also demonstrated115–117. 
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To prepare NLCs with high CUR loading and adequate stability, the complete solubilization 
of CUR in the used lipid mixture is necessary. Therefore, it was essential to investigate CUR 
solubility in the lipophilic mixture by varying the ratio of lipid components, thus the solubility 
of CUR at 5 and 8% w/w of the whole mixture was tested, modifying, in turn, lipid 
components ratios. 
NLC dispersions were prepared using one or the mix of two surfactants, as well as different 
amount of LM chosen. Nanoparticles mean particle size (Z-average), particle size distribution 
(PDI), and electrical charge (Z-potential, ζ) were analyzed to characterize the NLC 
dispersions and choose the one with the best parameters. In fact, DLS measurements provide 
the parameters usually investigated to value the colloidal system stability. Acceptable NLC 
dispersions have PDI values between 0.1–0.4, indicating that the lipid nanoparticles are 
monodispersed, with narrow population sizes, low variability, and no aggregation. Likewise, 
NLCs with Z-potential value close to -30 mV are considered stable because the electrostatic 
repulsion between particles with the same electrical charge prevents aggregation.  
The combined use of Tween 80 and Pluronic F-68 as surfactants had a high influence on the 
results, especially on PDI values since less width of the particle size distribution was 
observed. Due to a synergic action between the two emulsifying agents, mixed films formed 
on nanoparticle interfaces, leading to better surface coverage and increased viscosity and 
enhancing the long term stability of the formulation111,118. According to these conditions, M7-
300-TP showed the most suitable values for all the studied parameters and was chosen to 
prepare subsequent formulations. 
Since the aim of the work was to obtain a bifunctional nanocomposite also loaded with the 
antibacterial agent MTR, its physicochemical characteristics were also considered. MTR 
shows high solubility in water (10.61 mg/mL), particularly at a low pH, having pKa (basic) of 
2.49 and LogP = −0.02119,120. Therefore, it is conceivable that MTR could remain entrapped in 
the hydrophilic portion of the composite drug delivery system designed by us. However, its 
solubilization rate is low, and the risk of MTR not being wholly solubilized in the next step of 
sponge formation was high. Therefore, to be sure that the whole MTR dose (150 mg) was 
solubilized in the aqueous phase of the dispersion, MTR was added in the first step NLCs 
preparation, obtaining the sample M7-300-TP-MTR. The formulation was characterized and 
compared in terms of Z-average, PDI, and Z-potential to the others in order to evaluate MTR 
effects on these parameters. Both average particle size and PDI values decreased when MTR 
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was added to the formulation, while Z-potential values were not significantly affected by it. 
Thus, the M7-300-TP-MTR sample was further characterized. 
The SEM analyses on shape, the size and surface morphology of M7-300-TP-MTR showed a 
homogeneous dimensional distribution. Plus, no crystalline structures of MTR were observed, 
suggesting the absence of drug crystals in the dispersions. Some particle agglomerations were 
detected, probably due to the sticky nature of lipids as well as the treatment performed on the 
sample prior to the SEM analysis.  
CUR and MTR recovery (DR) were reckoned on fresh dispersion, while the entrapment 
efficacy (EE%) and loading capacity (LC%) of NLCs were indirectly determined by 
quantification of the free CUR in the aqueous phase (unentrapped) by both dialysis and 
ultrafiltration methods. The obtained results confirmed the high affinity of CUR towards lipid 
mixtures and optimal experimental conditions to produce NLCs. Regarding MTR, by the 
analyses, up to 94% of the drug was unentrapped, demonstrating that, during the NLCs 
synthesis, MTR remained in aqueous medium, and about 5% could be partitioned among the 
NLCs. However, this did not alter the NLCs characteristics. 
As regards the sponges, they were obtained entrapping M7-300-TP or M7-300-TP-MTR 
dispersions in a bioerodible hydrophilic polymers matrix and freeze-drying the samples. The 
matrix should be capable of adhering to the post-extraction socket tissues and swell once 
soaked by the physiological fluids, allowing the release of the antibiotic and the NLCs 
containing the antioxidant agent. This formulation was designed following two aims: (1) to 
allow the tissue penetration of CUR, otherwise insoluble in biological fluids, by its conveying 
into lipid nanoparticles; (2) to promote MTR prolonged loco-regional release in the post-
extractive socket to preserve aseptic conditions of the target. To achieve the latter purpose, 
suitable hydrophilic polymer matrices were formulated. A mixture of polymers, such as 
hyaluronic acid and PVP, was chosen to prepare a three-dimensional network to entrap NLC 
dispersion and obtain a solid composite such as a sponge by freeze-drying method. 
Hyaluronic acid (HA) was selected as biocompatible and biodegradable polymer, used in the 
dental field as wound healing and adjuvant in tissue regeneration121. Polyvinylpyrrolidone 
(PVP-K90) is one of the most utilized pharmaceutical polymers for its chemical and 
biological inertia. It has been shown to have an excellent affinity with mucins and a capability 
of forming solid matrix systems (e.g., films, tablets, discs) with enhanced mucoadhesive 
properties122,123. In addition, Trehalose (α-D-glucopyranosyl-α-D-glucopyranoside, TRH) a 
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hydrophilic and biocompatible sugar as a cryoprotective agent, was added. Due to the ability 
to establish hydrogen bonds with bio-structures, TRH is able to prevent the degradation of 
biological materials replacing water or interposing itself between water and them124. 
Sponge-A and Sponge-A-MTR were discarded for the excessive hygroscopicity, attributable 
to the too low amount of polymers, which did not allow the maintenance of separation among 
the lipid nanoparticles, leading to the mutual blending of them. On the other hand, the 
Sponge-C and Sponge-C-MTR resulted the least hygroscopic. 
The obtained multicomposite systems were characterized by a porous structure shaped by the 
water removal during the freeze-drying process, thus generating the vacant spaces, which 
contributed to the recognized large number of pores. Porosity is the collective term for these 
pores and their distribution in the structure of the solid. This morphological characteristic 
influences the ability to adsorb biological fluids as well as release drugs and nutrients 
embedded in it. The fluid absorption would be cooperative in controlling asepsis at the post-
extractive sockets125 and porosity causes an improvement in cell gas exchange, epithelium 
regeneration, exudates removal, and hemostasis126,127. Of note, that scaffold porosity has been 
reported as being more than 90% for tissue engineering applications128. 
Minitablets were designed to give to the formulation suitable form and dimension for the 
post-extraction socket to standardize the drug administration dose and to be easily placed into 
the target size. The reproducibility of the preparation method was confirmed by the obtained 
average tablet weight, diameter, and thickness, and by assessing the data following the Italian 
Pharmacopoeia [F.U. XII ed.] requirements.  
Swelling tests as weight and visual assessments were performed on to evaluate the 
morphological changes that may occur in the tablets once in contact with the post-extraction 
cavity fluids as well as water penetration and sponge hydration ability. The samples weight 
decreased after 15 min due to erosion phenomena of the gel layer and dissolution of MTR 
together with hydrophilic sponge components, that were removed together with the excess of 
artificial saliva during the experiment. 
Also, the frontal and radial visual assessments, performed to exclude any discomfort due to 
the morphologic changes and to ensure good patient compliance, showed a low aptitude of the 
minitablets to swell. 
Recently, non-transfusional hemocomponents have been more and more applied in several 
dental and oral surgeries procedures, such as the preservation of bone regeneration in post-
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extraction sockets129. The formulation was designed to be administrated in the target site 
wrapped in the L-PRF membrane, enhancing its well-known regenerative properties with the 
synergic action given by the simultaneous prolonged delivery of antibiotic and antioxidant 
compounds. 
The ability of the minitablet to promote CUR and MTR permeation rather than penetration in 
the L-PRF clot was evaluated in agreement with FDA and CE approved protocol (Intra-spin®, 
Intra-lock, Salerno, Italy). An increased permeation of the antibiotic was noticed, 
demonstrating its ability to cross the L-PRF membrane. In contrast, it was not possible to 
detect CUR in the same compartment, probably due to its poor solubility in the acceptor fluid 
and high affinity with the membrane where it remained entrapped. The extrapolated flux 
highlighted that L-PRF acted as the limiting factor for the free diffusion of MTR from the 
minitablet towards the post-extraction socket. Due to the modulation over time of the 
antibiotic release and the spreading in the neighbor gingival tissues, the aseptic conditions 
might have been maintained for a prolonged time in the areas involved in tissue regeneration. 
Moreover, the accumulation of the drugs in the membrane could validate that the new 
nanocomposite system acts as a drug reservoir able to release the actives in the surrounding 
tissues slowly. 
These permeations and the accumulation findings were strictly in accordance with our aim of 
obtaining a formulation able to slowly release anti-inflammatory and antibiotics agents, 
providing them in the target site for few days. 
To exclude any cytotoxic effects induced by the formulation, the in vitro viability assay on 
normal stromal cells HS5 was performed testing Sponge-C-MTR and comparing the results to 
empty sponge, prepared by the same process but without CUR and MTR.  
The results allowed defining the cytoprotective role of CUR and MTR. Although CUR is well 
known for the anti-cancer activity, this compound shows a biphasic effect on the stem cell 
proliferation, depending on the treatment concentrations and the type of stem cells used. It has 
been reported that bone marrow mesenchymal stem cells showed an increase in proliferation 
at CUR concentration up to 10µM, whereas a cytotoxic effect for higher concentrations 130. In 
our experiments, the tested concentrations of CUR, ranged to 0.61 and 3.66 µM, were below 
than the cytotoxic condition, thus suggesting a protective effect of CUR on cells and making 




In the light of described results, it could be concluded that this synergistic effect can be a 
potential strategy to overcome the antibiotic resistance mechanism that may occur with the 
MTR oral administration and improve the CUR delivery, supporting and enhancing the role of 
hemocomponents for the tissue regeneration in the dental and oral fields. 
Regarding the innovative protocol of guided bone regeneration studied, the promising results 
support the action of L-PRF and its derivates in bone regeneration and ridge preservation, 
beyond that the oral surgery in general. However, further studies will be necessary to provide 
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